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Abstract
RNAi (RNA interference) is emerging as a promising tool for cancer therapy. Small
interfering RNA (siRNA) molecules are activated in that pathway to reduce specific tumour
cell RNAs that mediate malignancy. SiRNA treatment has been primarily limited to in vitro
studies: lack of efficient, preferential in vivo delivery to target cells remains a major obstacle.
Many human tumours overexpress folate receptors (FR), and siRNA-mediated reduction of
thymidylate synthase (TS) sensitizes tumour cells to anti-TS drugs. I developed a folatecontaining cationic liposome to preferentially deliver anti-TS siRNA to FR-expressing
human tumour cells. I show, in vitro, that liposome-encapsulated siRNA (but not free
siRNA) is delivered to human tumour cells, and that FR-targeting liposomes preferentially
deliver siRNA into FR-positive human tumour cells. However, liposome-delivered siRNA
did not reduce TS mRNA, an obstacle that must be overcome before the advantage of
preferential siRNA delivery can be realized in vivo.

Keywords
Cationic liposomes, folate receptor, cancer, small interfering RNA (siRNA), RNA
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Chapter 1

1

Introduction

Preamble
The purpose of this introduction section will be to establish the basic principles
encompassing antisense therapy with emphasis placed on the delivery challenges limiting
their effective application in an in vivo setting. Initially, I will give a brief overview on
the history (Section 1.1) and mechanism (Section 1.2) of the RNA interference (RNAi)
pathway and its exploitation in disease treatment (Section 1.3). Emphasis will be placed
on RNAi effector molecules: small interfering RNAs (siRNAs) and their application(s) in
cancer therapeutics (Section 1.4) and specifically targeting thymidylate synthase (TS), an
enzyme recognized as mediating malignant characteristics and well-established as a
target of multiple anticancer drugs (Section 1.5). I will then discuss the inherent
challenges to antisense delivery (Section 1.6), referencing several common delivery
strategies (Section 1.7.1-1.7.2) before focusing on the use of liposomes as they pertain to
this project (Section 1.7.3). Finally, I will talk about the use of targeting moieties to
enhance liposome-antisense delivery (Section 1.8) and specifically the benefits and
challenges of decorating liposomes with folate to exploit the folate receptor on cancer
cells (Section 1.9).
1.1 Discovery and history of RNA interference
The discovery of the RNA interference pathway is the culmination of the work of
many scientific groups. In an attempt to circumvent problems inherent in classical genetic
analysis using mutant variants, Izant and Weintraub investigated the ability of expression
vectors directing production of antisense RNA (i.e., RNA complementary to mRNA
encoding information essential for production of protein) to inhibit thymidine kinase
(TK) gene activity in eukaryotic cells. They discovered a 4-fold reduction of transient TK
expression in TK- mouse L cells micro-injected with expression vectors containing DNA
directing production of TK mRNA and, coincidentally, RNA antisense to TK mRNA,
compared to control cells injected with the same TK mRNA expression vector but a
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second vector producing control RNA that was not complementary to TK mRNA1.
Similarly, Fire and colleagues reported that DNA fragments inserted into expression
vectors in reverse orientation could produce antisense RNA molecules that interfered
with gene expression in Caenorhabditis elegans2. In plants, posttranscriptional gene
silencing was achieved through nucleic acids of either foreign or endogenous origin,
where a reduction of RNA molecules similar in sequence to introduced DNA was
observed3,4. Then in 1998, a significant advancement took place in the field of RNAi
when Fire and Mello reported that the introduction of only a few strands of doublestranded RNA could cause potent and specific gene inhibition in C. elegans5. The finding
of the causative agent for this phenomenon, which they called RNAi, earned them a
Nobel Prize in Physiology or Medicine in 2006.
1.2 Mechanism of action of RNAi
Although genomic sequencing may reveal more in the future, there are currently
three major classes of small regulatory RNAs that have been recognized as naturallyoccurring antisense molecules: short interfering RNAs (siRNAs), microRNAs (miRNAs)
and PIWI-Interacting RNAs (piRNAs) (Figure 1.1). For the purposes of this thesis, only
siRNAs will be discussed in detail (all three classes involved in RNAi are reviewed in
detail by Jinek and Doudna6). SiRNA molecules are typically characterized as being
approximately 20-30 nucleotides in length7 and are generated from longer doublestranded RNA precursors that are processed by Dicer, a evolutionary conserved enzyme
from the RNase III family of nucleases, in the cytoplasm of cells8. Studies have shown
that a significant proportion of the mammalian genome is responsible for coding
endogenous antisense transcripts9,10, however, synthetic siRNA molecules have also been
constructed and transfected into cells7. The resultant siRNA molecules contain a
characteristic 5’-monophosphate group and 3’ dinucleotide overhang, critical for loading
into the RNA induced silencing complex (RISC)11. In the processed siRNA duplex, one
strand is preferentially selected as the “guide” strand for RISC loading, while the
“passenger” strand is inevitably cleaved by the argonaute-2 protein (Ago2), thus
facilitating its release and RISC activation12,13. Asymmetrical strand selection to guide
RNAi depends on the thermodynamic stability of the 5’ end with the less
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Figure 1.1. Three classical categories of antisense molecules and their respective
precursors. A) long double stranded RNA (dsRNA) before being processed into small
interfering RNA (siRNA). B) original micro RNA containing poly-A tail and loop
structure before being cleaved. The bubbles denote mismatches in base pairs and the
miRNA* nomenclature indicates the passenger strand. C) PIWI-interacting RNA
(piRNA) cycle regenerating antisense piRNA strands from reciprocal cleavage of sense
and antisense transposon transcripts6.

4

5

thermodynamically stable 5’ strand being selected as the guide strand. In fact, it has been
shown that a difference of a single hydrogen bond can direct strand selection14. In
humans, RISC loading and recruitment of Ago2 recruitment (the catalytic enzyme in
RISC responsible for target RNA scission) requires association of TRBP (the human
immunodeficiency virus transactivating response RNA-binding protein) with siRNA
bound to Dicer. This suggests that Dicer, Ago2 and TRPB are all involved in the RISCloading complex15. Ago2 and single-stranded siRNA together alone form a minimal
RISC that could accurately cut target RNAs16, while determination of the crystal structure
of Argonaute protein from Pyrococcus furiosus revealed distinct N-terminal, middle and
PIWI domains with a Piwi Argonaute Zwille (PAZ) domain connected above the base via
a “stalk” region. The PIWI domain resembles ribonuclease H, suggesting its function as
“Slicer” responsible for target cleavage17. Further analysis of the crystal structure of
Thermus thermophilus argonaute revealed the guide strands 5’-phosphate end is anchored
in the Mid domain, while the 3’ end is anchored within the PAZ domain. This orientation
permits Watson-Crick base-pairing with target mRNA between nucleotides 2-6 and
cleavage at the 10-11 position18. Based on sequence similarity between the siRNA
molecule and target mRNA, the mRNA transcript is either enzymatically cleaved (exact
base pairing) or translationally repressed (inexact base pairing), however, the mechanism
has not been completely illuminated19,20. The factor determining whether target RNA is
degraded, or translationally repressed without degradation, is thought to depend on the
degree of sequence matching between the siRNA and its target mRNA21. Perfect matches
are thought to result in mRNA degradation while imperfect matches lead to translational
repression. However, this rule is not always followed22. A schematic outlining the role of
siRNA role in the RNAi pathway can be seen in Figure 1.2. Additionally, it is also
important to note, especially when considering the issue of the amount of siRNA
potentially needed to exert a therapeutic effect when siRNA-mediated reduction in
disease-potentiating genes is proposed as a treatment strategy, that RISC is able to
catalyze several rounds of RNA cleavage leading to gene silencing from only a few
molecules of siRNA per cell2,23.

6

Figure 1.2. Schematic of siRNA being processed by Dicer and repressing mRNA
translation through RISC.
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1.3 siRNA therapy in disease treatment
Since every cell in the body possesses the intrinsic machinery required to process
endogenous RNAi molecules and exogenous molecules designed to mimic endogenous
RNAi24, and any RNA sequence can theoretically be targeted, there exists a plethora of
diseases resulting from abnormal gene expression that could be suitable candidates for
siRNA therapy. In general, antisense research has focused on areas where standard
treatment options have been relatively ineffective or where improvement is desired and
required. The list of diseases, infections, and pathological conditions in this category
includes, but is not restricted to, viral infection25,26, age-related macular (AMD)
degenerative diseases27, cancer28,29 (discussed further below), neurodegenerative
diseases30, Duchenne Muscular dystrophy31, and Huntington Disease32. SiRNA strategies
have also become powerful research tools to explore the consequences of gene silencing
on disease progression. In one study, Karlas and colleagues utilized a genome-wide
siRNA library composed of ~60,000 siRNAs targeting over 20,000 gene products to
determine which host cell genes are critical for Influenza A virus replication33. Their
conclusion was that siRNA therapy has enormous potential to generate increased
understanding and to be applied to treatment of many diseases. The actual
implementation of siRNA strategies is easier said than done, however, since factors such
as tissue accessibility and siRNA delivery remain obstacles. Those factors are addressed
below.
1.4 siRNA in cancer therapy
In Hanahan and Weinberg’s prominent paper on the Hallmarks of Cancer, one of
the enabling characteristics contributing to cancer development is genome instability and
mutation34. A central concept is that certain mutant genotypes will provide an advantage
over other cells, and that those advantageous characteristics lead to their growth and
dominance in the local environment. Whether it is the activation or upregulation of
certain oncogenes or the downregulation of tumour suppressor genes (both are events
leading to tumour progression), both are situations where siRNA strategies may be
utilized to modulate abnormally-expressed genes. Conventionally, siRNA strategies are
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employed to silence mRNA targets resulting in loss of gene function, however,
alternatively they may also be utilized indirectly to upregulate certain genes of interest35.
This can potentially be achieved by targeting miRNAs, which normally function to
regulate over 100 different mRNA transcripts36. This may become even more critical
when trying to target disease-causing gene products previously considered “nondruggable” through application of standard strategies employing small molecules,
proteins or antibodies to bind to and alter the activity of target molecules37. In some
cases, treatment with siRNAs has led to the direct inhibition of cancer cells both in vitro38
and in vivo39, while in other instances the use of siRNAs has re-sensitized cancer cells to
chemotherapeutic drugs that have arisen during chemotherapy38,40, This is especially
valuable when trying to reduce effective drug doses of chemotherapeutic drugs to limit
side effects on patients. MacKeigan and colleagues used an RNAi screen to identify over
650 human kinases and 220 phosphatases potentially implicated in apoptosis and
chemoresistance, and were then able to subsequently downregulate a selected few and
show enhanced apoptosis in cancer cells treated with low doses of the chemotherapeutic
drug Taxol41, The ability to perform these robust RNAi screens using siRNA libraries is
beginning to be even more critical as improvements in sequencing has revealed the
highly heterogeneous nature of many cancer types and the abundance of genetic
mutations they carry42. As a result, the development of more proficient tumour
sequencing technology and the ability of siRNAs to, in theory, target any gene may allow
for more effective personalized treatments where conventional therapeutic strategies are
not sufficiently effective and/or are accompanied by toxicities such that cancers cannot be
cured or controlled to a satisfactory degree.
1.5 Targeting thymidylate synthase (TS) in cancers
With advancements in sequencing, bioinformatics and diagnostic tools such as
those described above, genome-wide siRNA screens the discovery of cancer-associated
genes is ever-growing43,44. Some of the gene targets undergo mutations prominent in
specific cancer types (for example, a BRAF mutation occurring in 66% of malignant
melanomas45), while others are more generally implicated in cancer progression (for
example, those playing prominent roles in signaling pathways that control growth and
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proliferation of a large fraction of tumour types). An example of a general target
receiving attention is Ras, part of the mitogen-activated protein kinase (MAPK) pathway,
which is mutated in approximately 15% of human cancers44. Another popular target is
vascular endothelial growth factor (VEGF), due to its role in facilitating increased blood
supply for tumour growth resulting from a transition from a dormant to active
vascularization state. Reductions in tumour volume have been limited with the use of
antiangiogenic agents alone. However, studies utilizing combinations of antiangiogenic
molecules, such as those targeting thrombospondin-1 and VEGF, appear to be more
promising46.
A putative siRNA target that has been well implicated in many cancers is
thymidylate synthase (TS). TS protein enzymatically functions to catalyze the reductive
methylation of deoxyuridylate (dUMP) to produce thymidylate (dTMP) with the N5,N10methylenetetrahydrofolate (CH2-THF) acting as the methyl group donor (Figure 1.3)47.
Both normal and cancerous cells depend upon the TS-catalyzed reaction for DNA
replication and repair as it provides the only de novo source of dTMP. With the enhanced
reliance of cancer cells on TS for a source of dTMP in DNA replication during
uncontrolled proliferation, TS has proven to be an attractive therapeutic anticancer target.
Surprisingly, use of traditional TS protein small molecule inhibitors can actually lead to
transiently elevated TS protein levels and subsequent drug resistance as depicted in
several 5-fluorouracil (5-FU)-selected, drug resistant cell lines48. This is likely due, in
part, to disruption of the autoregulatory feedback loop between TS mRNA and TS
protein, whereby exposure to TS protein inhibitors leads to a decrease in intracellular
unbound TS, resulting in enhanced TS mRNA translation and ensuing elevated TS
protein levels49. Issues of TS protein drug resistance in many cases coupled with
unwanted toxicity profiles have warranted an alternative approach to targeting TS
function in cancer therapy. By targeting TS at the mRNA level problems of
autoregulation and protein translation can theoretically be ablated, making an antisense
approach attractive as a component of TS-targeted therapy. Initially, synthetic antisense
oligodeoxynucleotides (ASOs), which facilitate mRNA degradation via ribonuclease H
activation and exonuclease cleavage50, were implemented for TS mRNA silencing due to
their enhanced stability through a 2’-O-(2-methoxyethyl) backbone modification51. These
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Figure 1.3. Reductive methylation of deoxyuridylate (dUMP) to produce
thymidylate (dTMP). N5,N10-methylenetetrahydrofolate (CH2-THF) acts as the methyl
group donor.
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ASOs enhanced cancer cells to TS inhibitors and reduced cell proliferation when used
alone in vitro52. They were also able to reduce both TS mRNA and protein levels in
tumour tissues when administered intraperitoneally52. As an alternative to synthetic ASOs
and perhaps offering a more natural and potent route53, siRNAs have more recently been
tested to reduce TS levels. In vitro, TS siRNA alone was able to reduce mRNA and
protein levels over 80% and in combination with pemetrexed significantly reduced cell
proliferation28. The effectiveness of using siRNAs targeting TS or any other gene,
however, has largely been restricted to cell culture as problems arise when delivering
siRNA in vivo.
1.6 Challenges associated with antisense delivery
As mentioned above, ASOs are capable of accumulating in cultured cells in the
absence of delivery agent (although only at relatively high concentrations that also induce
toxicity; liposomal delivery vehicles are generally required to mediate uptake of lower,
non-toxic concentrations)54 and in tumour tissue in vivo, which take up ASOs relatively
efficiently without the use of exogenous delivery agents55. Alternatively, siRNAs are
transfected into recipient cells in culture using a standard transfection agent such as
Lipofectamine 2000. Administration of naked siRNA (no delivery agent or molecule
modification) in vivo is inefficient for a number of reasons, especially when systemically
administered, including: (1) limited cellular uptake across the plasma membrane due to
repulsion of negative charges; (2) non-specific distribution and uptake into non-tumour
tissues; (3) serum nuclease-mediated degradation; (4) reticuloendothelial system (RES)
capture and renal elimination; and (5) inefficient capillary escape into tissues
(extravasation)56,57.
Consequently, to be implemented in vivo, siRNA molecules are usually
administered in conjunction with some type of delivery agent. However, any
systemically-delivered nanoparticle siRNA delivery agent must still overcome many
hurdles: first it must evade filtration/renal excretion, phagocytosis by circulating and
tissue-resident white blood cells, and degradation by plasma nucleases in the
bloodstream. Thus it must be capable of movement across the vascular endothelial layer;
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diffusion through the extracellular matrix (ECM); uptake by target cells; escape the
endosome; and, finally, productive association with RNAi-processing complexes in the
cytosol (Figure 1.4)58,59. Following systemic administration, siRNA delivery
nanoparticles are preferentially taken up by the reticuloendothelial system (RES)
composed primarily of macrophages and Kupffer cells present in RES organs such as the
spleen and liver60. This process is further enhanced by serum proteins adsorbing to the
surface of nanoparticles, thus promoting opsonization (complement activation) and rapid
clearance61. Factors such as particle size, charge and surface properties can influence
clearance and biodistribution (discussed in the section on PEGylating liposomes [Section
1.7.3]). During siRNA biodistribution, siRNA particles leave blood vessels and enter the
tissue interstitium. Diffusion across capillaries results from the difference in hydrostatic
and osmotic pressures on either side of the blood vessel membrane. The type of
endothelium in blood vessels also comes into play as major differences occur between the
three types: continuous (e.g., arteries, capillaries); fenestrated (e.g., digestive mucosa);
and discontinuous (e.g., liver)61. One advantage when trying to target tumours with
siRNAs or other therapeutic molecules is their “leaky” vasculature compared to normal
tissues. Tumour microvessels can have pores ranging from 100 to 780 nm in diameter,
while normal capillaries can have pores <6 nm, which is why optimizing particle sizes
can become important58. Leaky vasculature and lack of lymphatic drainage (characteristic
of most solid tumours) has led to recognition of the Enhanced Permeability and Retention
(EPR) effect, whereby systemically injected particles will tend to accumulate at the
tumour site. One tradeoff, however, is that a lack of a lymphatic system actually increases
interstitial fluid pressure from the centre of the tumour outward making passive diffusion
of particles through the interstitium to the tumour border more difficult62. Once the
nanoparticle reaches the tumour cell it must cross the cell's plasma membrane into
cytoplasm. This is another major advantage to using a delivery agent, as naked siRNA is
not favourably taken up across anionic cell membranes due to its high molecular weight,
large size, and negatively charged phosphate backbone. Functionalizing siRNA carriers
with ligands or antibodies can promote specific uptake and will be explored further when
discussing targeting moieties (Section 1.8). Positively charged siRNA carriers generally
associate with the negative plasma membrane and are internalized in cytoplasmic lipid
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Figure 1.4. Barriers associated with various siRNA delivery methods. The three
major areas depicted include circulation in the bloodstream, cellular uptake and
intracellular trafficking58.
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vesicles (endosomes) via endocytosis63. Upon internalization, the endosome will typically
fuse with early endosomes before maturing into late endosomes and fusing with
lysosomes for degradation. It is imperative that the siRNA/nanoparticles escape the
endocytic vesicle prior to lysosome processing, otherwise they will be degraded before
reaching the RNAi processing complex in the cytosol. A great deal of effort has gone into
understanding the principles of endosomal escape and what properties promote it.
Currently, it is hypothesized that there are two modes for siRNA carriers to facilitate
endosomal escape: (1) polyplexes favour the proton sponge effect and umbrella
hypothesis; while (2) lipid vesicles favour membrane destabilization via ion pair
formation64. Briefly, cationic polyplexes are able to promote escape by acting as good
buffering agents at pH 5-7. Normally, as early endosomes progress to late endosomes and
eventually to lysosomes, the pH is lowered. However, by acting as buffers the polyplexes
prevent acidification (they act as "proton sponges”) in the endosomes, resulting in proton
influx and osmotic swelling65. This hypothesis has been further extended to include the
umbrella hypothesis, whereby the polyplexes become protonated at a lower pH (5-6)
causing a change in their conformation due to electrostatic repulsion of their recently
protonated amine groups64,66. This extension coupled with the increase in osmotic
pressure due to the “proton sponge” effect is presumed to facilitate endosomal rupture
and escape. Alternatively, cationic lipid vectors are thought to promote endosomal escape
via interactions with the anionic phospholipids forming the endosome. Close proximity of
the cationic liposome lipids and anionic endosome lipids it thought to result in
destabilization and formation of cationic-anionic ion pairs67. This new configuration
presumes a cone shape and promotes the transition from a lamellar phase to an inverted
hexagonal phase, which can be likened to the physical opening of a “zipper” with the
siRNA content being released to the cytosol68. Regardless of the mode of endosomal
escape, this barrier remains a major obstacle to efficiently delivering siRNA to RNAi
processing complexes in cells.
Currently, siRNAs in clinical trials have been limited to local administration at
sites near target tissues, such as the eye. Alternatively, they have taken advantage of the
natural biodistribution of nanoparticles following systemic injection (for example, in
testing siRNAs for treatment of liver cancer)(see Table 1.1 for examples of various
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Table 1.1. Selection of siRNA therapies using various delivery techniques that
currently or recently completed clinical trials. Legend: IV – intravenous injection; IVT
– intravitreal injection; VEGF – vascular endothelial growth factor; PLK1 – polo-like
kinase 1; KSP – kinesin spindle protein; PKN3 – protein kinase 3; RRM2 –
ribonucleotide reductase; GM-CSF – granulocyte-macrophage colony stimulating factor;
EphA2 – receptor tyrosine kinase; SNALP – stable nucleic acid lipid nanoparticle; AMD
– age-related macular degeneration; NAION – non-arteritic anterior ischemic optic
neuropathy; term – terminated; ongo - ongoing
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siRNA delivery systems in clinical trials, and www.clinicaltrials.org for a complete list of
siRNA therapies being tested in humans). These methods, however, are not viable for
many specific cancers or other diseases, due to poor local accessibility and/or nonadvantageous patterns of tissue distribution after systemic administration. After
discussing the many inherent barriers involved with the systemic delivery of siRNA
delivery agents it is not surprising that an ideal delivery system should possess most or all
of the following attributes: (1) safety: biocompatible, biodegradable and nonimmunogenic; (2) capacity to enhance tissue-specific distribution following intravenous
injection; (3) deliver an effective amount of siRNA into target cells while protecting them
from serum nuclease degradation and RES clearance; and (4) promote endosomal release,
thus permitting the association of siRNA with RNAi machinery, and 5) be relatively
simple and inexpensive to manufacture57,58. It is important to keep these general
characteristics in mind when considering the advantages and limitations to the common
siRNA delivery strategies described below.
1.7 Overview of common siRNA delivery systems
SiRNA delivery systems are broadly categorized as either viral or non-viral
methods. For this project, only those methods considered non-viral will be explored. The
non-viral methods can be further divided into 3 categories: physical, conjugationmediated, and carrier-mediated. The last of these three will be discussed in more depth as
it relates to this project.
1.7.1 Physical delivery methods
One of the more straightforward and initial methods to deliver siRNA is via
hydrodynamic injection. This method involves the intravascular injection of siRNA
typically suspended in an aqueous buffer solution69. The advantage of this method is that
siRNAs can be locally administered and concentrated in specific tissues, thus avoiding
many obstacles (discussed above) associated with systemic delivery strategies. Typically,
in murine models, a 10% injection volume to body mass ratio is administered70.
However, and depending on the organ and injection site, this can be successfully lowered
to <2%, as observed when attempting to achieve gene silencing in the liver through
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hepatic portal vein injection71. Due to its invasive nature, hydrodynamic injection is not a
realistic option for treatment of many disease types. However, there are a few situations
(for example, age-related macular degeneration [AMD]) where some success has been
achieved. Generally, intravitreal treatment with siRNAs is well tolerated by patients and
has even helped to improve visual acuity72,73. Even though there are multiple sites
surrounding the eye into which bioactive agents can be injected and from which those
agents can be released into their site of action, it is still thought that the development of
advanced nanocarriers can provide a more effective delivery system than ocular
injections alone72. Such nanocarriers are now receiving more attention in planning
strategies to apply siRNAs in a clinical setting.
Another method, termed electroporation (EP), uses electrical pulses to facilitate
the cellular uptake of material into cells74. The pulses are believed to create transient
aqueous pores in the plasmid membrane, thus making them more susceptible to transit of
macromolecules such as nucleic acids75. Its attractiveness stems from the ability to
restrict delivery within a given area (electric field) with minimal side effects76. EP may
not be suitable for all situations, including treatment of tumours deep within the body.
However, EP-mediated transfection of VEGF-targeting siRNA was able to suppress
tumour growth by 90% in mice77, and dermal EP of siRNA has been optimized to reduce
GFP signal by 50% in guinea pig75.
A final method of physical delivery worth noting is the phenomenon of
mechanical massage, whereby the application of light, physical pressure to an organ
enhances exogenous nucleotide uptake from intravenous circulation. Initially shown to be
effective in mice, with increased renal uptake following intravenous injection and later
repeated in the spleen, this method is hypothesized to physically activate certain
transcription factors that increase the accumulation of nucleic acids in the cells of the
massaged tissue78,79.
1.7.2 Conjugation-mediated delivery
Another strategy taken to increase the delivery efficiency of siRNA is to
conjugate them with a variety of moieties (e.g., small molecules, peptides, antibodies, or
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aptamers) that improve stability and increase the time in circulation, increase the
specificity of tissue accumulation, and increase cellular uptake and/or endosomal
escape80.
For example, the small molecule cholesterol was conjugated to the 3’ end of
siRNA (chol-siRNA) before being intravenously injected in mice. The modified cholsiRNA) displayed enhanced serum stability, reduced plasma clearance and significant
levels were detected in liver, heart, kidney, adipose and lung tissues 24 h following
injection compared to the unmodified siRNA37. Recently, Parmer and colleagues
conjugated poly(amido amine disulfide) polymer on the 5’ end of the passenger siRNA
strand to enhance endosomal lysis and escape. They also took advantage of the acidic
nature of endosomes to reduce cytotoxicity by additionally conjugating an acid labile
poly(ethylene glycol)(PEG) molecule to mask the lytic activity of the polymer81.
Cell-penetrating peptides (CPPs) may also be complexed or conjugated with
siRNA to increase their uptake across plasma membranes. They are typically amphipathic
or cationic in nature, which aids them in transfer across the plasma membrane. Although
still a controversial concept, it appears they are taken up via both endocytic and nonendocytic mediated pathways82. Conjugation of the CPPs penetratin or transportin to
siRNA showed competitive target knockdown and better sustained gene silencing over 3
days compared to commercially available lipid-mediated transfection agents
(Lipofectamine) in vitro83.
Association of antibodies with siRNA has been shown to enhance tissue specific
targeting. Xia et al. first demonstrated in human epithelial cells an over 90% reduction in
luciferase signal target following uptake of monoclonal antibody (mAb) against human
insulin receptor conjugated to anti-luciferase siRNA84. They expanded on this work in
vivo by achieving a 69-81% reduction in luciferase gene mRNA levels in rat glial cells
implanted in adult rat brains using a transferrin receptor targeting mAb conjugated to
siRNA85.
An emerging siRNA delivery strategy utilizes the conjugation of oligonucleotides,
called aptamers, for increased delivery efficiency. Aptamers function in a fashion similar
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to small molecules in that they are about the same size and therefore display similar
clearance patterns. However, they also share characteristics with antibodies in that they
tightly bind to targets in a specific manner and can modulate downstream pathways86.
Aptamers can be designed against numerous targets and have the ability to differentiate
between tumorigenic and normal cells86. Due to their ability to affect downstream
regulators, aptamers alone are used to treat a number of diseases. However, their efficacy
is believed to be improved when functionalized with other therapeutic molecules such as
siRNA. The most well-studied of these aptamer-siRNA chimeric molecules are those
designed to bind to cells expressing cell-surface receptor prostate specific membrane
antigen (PSMA), a transmembrane protein highly expressed in human prostate cancer.
“Second generation” PSMA-siRNA chimeras contain a truncated PSMA binding region
that allows for large-scale synthesis while maintaining specificity; a 2-nt overhang on the
siRNA 3’ end guide strand for greater accessibility to RISC; and an additional
conjugation to PEG to increase serum stability for up to 5 days. These modifications
resulted in significant regression of PSMA-positive tumours in athymic mice following
intravenous injection87. Since aptamers are composed of nucleotides they face many of
the same challenges as siRNAs. It is anticipated that further modifications to both
aptamers and siRNAs will lead to potent anti-cancer chimeric molecules.
1.7.3 Carrier-mediated delivery
Carrier-mediated delivery vehicles are similar to conjugated ones in that they
facilitate siRNA uptake into target tissues, with the difference that the siRNA and carriers
do not form covalent complexes with the siRNA as the conjugate vehicles do. There are
many types of nanoparticles that could be considered carriers for siRNA. For the
purposes of this project, only carbon nanotubes (CNTs), polymer carriers, and lipidderived carriers will be discussed.
Carbon nanotubes (CNTs) are highly ordered, hollow carbon graphite
nanomaterials shaped in a nano-needle structure giving them a large surface area for
interactions88. Their shape would suggest they facilitate cellular uptake through physical
penetration of the plasma membrane. However, recent studies indicate they enter via
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endocytosis88. CNTs are capable of forming stable complexes with siRNA molecules
through a mechanism driven by Van der Waals interaction whereby the siRNA duplex
partially “unzips” and wraps around the CNT wall89. Alone, CNTs display poor
dispersion and solubility in aqueous solutions: functionalized CNTs (f-CNTs) have been
synthesized to solve these problems. An example of an f-CNT is the addition of PEG to
the outer wall, which improves overall stability and hydrophilicity90. F-CNTS coated
with PEG and an acid-labile disulfide group to enhance endosomal escape showed a
higher silencing efficiency then the standard commercial transfection agent
Lipofectamine. Much more work is needed with CNTs before they can become viable
siRNA delivery vehicles in vivo91.
Cationic polymer delivery agents form strong electrostatic interactions with
negatively charged siRNAs, thus forming polyplexes where the siRNA becomes
condensed and protected from nuclease degradation91. Cationic polymers can be
categorized as either natural or synthetic. Natural polymers have the inherent advantage
of being biocompatible, biodegradable, and minimally toxic, while synthetic polymers,
although designed to achieve high endosomal release and low enzymatic degradation,
often exert undesirable toxicity57. Atelocollagen, an example of a natural polymer, when
complexed with siRNAs targeting candidate genes of prostate cancer and administered
systemically, induced selective and efficient inhibition of tumour growth in mice. The
atelocollagen/siRNA complexes also showed great stability, remaining intact for over 3
days while incurring no significant side effects or interferon response92,93. Poly-L-lysine,
or polyethyleneimine (PEI), is the most studied synthetic polymer for delivering antisense
molecules58. As a cationic polymer with a high charge density, PEI takes advantage of the
“proton sponge effect” for efficient endosomal escape64. PEIs have been synthesized with
various degrees of branching and molecular weights. Generally, a branched structure
results in a higher transfection efficiency, while low molecular weight structures confer
lower toxicity94. Urban-Klein and associates were able to reduce subcutaneous tumour
growth in mice using a low molecular weight PEI complexed with siRNA targeting cerB2/neu (HER-2) receptor administered intravenously. The PEI/siRNA complexes were
able to shield the siRNA from serum nucleases and did not induce any apparent toxicity
to animals95. Similarly, systemic administration of a low molecular weight/siRNA
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complex targeting VEGF did not induce liver damage or induce cytokines, but did
efficiently deliver siRNA to subcutaneous tumours of pancreatic and prostate origin96.
Recent strategies to further advance the efficiency and safety of cationic polymers
include: combining them with liposomes (lipopolyplexes)97; functionalizing them with
PEG98; and coating them with gold nanoparticles (AuNPs)99.
Liposomes are spheroid vesicles composed of a phospholipid bilayer and aqueous
core. Due to their inherent amphipathic nature and well-studied pharmaceutical
properties, liposomes have became attractive carriers for siRNA and other antisense
molecules.56 While anionic, neutral and cationic liposomes have all been synthesized for
siRNA delivery and have resulted in some successes (including initiation of a clinical
trial using neutral liposomes)100, the general emphasis has been on cationic liposomes
because of their efficient delivery of siRNA to cells. This is because stable complexes
can naturally form from the electrostatic interaction of the positive lipids and negative
siRNA molecules; the interaction of the positive lipids and negative plasma membrane
during cellular uptake; and the mechanism by which the positive lipids facilitate
endosomal escape once inside the cell58. The addition of negatively charged siRNA to
cationic lipids spontaneously forms stable multilamellar structures that protect siRNA
from serum nucleases and facilitates their uptake in cells101. There are numerous cationic
lipids available that vary in the number of amines in their head group capable of being
protonated (an event that affects siRNA binding and overall surface charge); the
orientation between the head group and backbone; and the overall nature of the
hydrophobic backbone itself (length and saturation)102. The addition of a helper neutral
lipid such as dioleoylphosphatidylethanolamine (DOPE) or cholesterol helps by allowing
the complex to adopt a nonbilayer structure: this is thought to be critical for transitioning
to an inverted hexagonal phase and to ion pairing formation with the endosome, both of
which facilitate siRNA release (previously described in Section 1.6)27,103. The size of the
liposome particles is also an important factor. Considering the leaky vasculature of the
tumour environment that results from the EPR effect, and the restrictions on siRNA
carrier size imposed by serum clearance and RES entrapment, there is still a debate on the
acceptable size limit of particles. While many believe 200 nm is appropriate as an upper
limit, one study using synthetic 3D models to mimic the interstitial milieu suggested that

26

particles <100 nm were required to effectively and rapidly diffuse through membranes
and tissues to reach target cells104. The size can largely be controlled through the
synthesis process, which can range from the classic lipoplex protocol, to passive
encapsulation or ethanol dilution (see Figure 1.5)104.
While cationic liposomes can enhance cellular uptake and endosomal release,
their positive charge unfortunately enhances aggregation and opsonization in the
bloodstream leading to RES uptake and decreased serum half lives105. This is what led to
the advancements in the functionalization of liposomes such as the addition of PEG.
These PEGylated liposomes have been shown to increase the overall transfection
efficiency to prostate tumour xenografts in vivo by preventing systemic clearance and
serum opsonization (see Figure 1.4)105. However, the incorporation of PEG was not
without limitations. Repeated injections appeared to induce anti-PEG IgM, leading to
accelerated blood clearance106. The generation of anti-PEG IgM did seem to become
attenuated when siRNA was encapsulated in the core of PEGylated liposomes (i.e.,
passive encapsulation method) versus complexation of siRNA to the outside of the
liposomes (i.e., lipoplex method)107. The presence of PEG on the surface of cationic
liposomes has also been shown to inhibit cellular uptake and endosomal escape as it
partially shields the positive charge. In fact, a 5 mol% solution of 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000 (DSPE-PEG-2000)
completely abolished gene silencing and was not reinstated until the fraction was lowered
to 1-2 mol%60. These issues have led to recent advancements in particle design such as
the creation of stable nucleic acid-lipid particles (SNALPs), which contain a mixture of
cationic and fusogenic lipids initially stabilized by a PEG coating. Following intravenous
administration, the PEG coating is shed and the cationic interior remains, leading to
increased transfection efficiency108. Tekmira Pharmaceuticals has further advanced
SNALP technology by synthesizing the ionizable cationic lipid 1,2-dilinoleyloxy-3dimethylaminopropane (DLinDMA). A derivative termed DLin-KC2-DMA has now
been developed, and shows heightened endosomal escape via a strong propensity for
undergoing an inverse hexagonal transition at acidic pHs109. This technology has been
implemented in a phase 1 clinical trial to treat primary and secondary liver. However,
results are not yet published (see www.clinicaltrials.org for study details). Another
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Figure 1.5. Illustration of common liposome synthesis techniques. The figure
illustrates the fact that a higher percentage of siRNA molecules become encapsulated in
the liposome when using the passive encapsulation method compared to the lipoplex
method. Legend: SUV – small unilamellar vesicle
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strategy to further enhance liposome/siRNA delivery, especially with regard to specificity
(discussed above) is the inclusion of a targeting ligand capable of binding specifically to
a tissue/tumour specific marker or receptor. This is discussed in the following section.
1.8 Ligand targeting nanoparticles for enhanced uptake
Similar to the methodology underlying targeting conjugated delivery vehicles,
liposomes can also be functionalized with different ligands to enhance cellular uptake in
specific tissues. For example, while non-targeting PEGylated liposomes resist
aggregation and have long half-lives they still end up in normal tissues as well as
tumours: less than 5% of the initial dose is taken up by the tumour110. That is why, in the
case of Tekmira Pharmaceutical’s SNALPs, those agents are currently only in
development to target liver cancer because, physiologically, that is where the majority of
nanoparticles will naturally accumulate60. Davis and colleagues, with the backing of
Calando Pharmaceuticals, has a cyclodextrin polymer-based drug (CALAA-01) currently
in phase 1 clinical trials: this is the first siRNA therapy systemically administered and
targeted to transferrin-expressing solid tumours111. It is important to keep in mind that the
targeting ligands to not direct the particles to specific tissues. However, they do enhance
the uptake in the targeted tissues once they get there through receptor-mediated
endocytosis. This was shown when both transferrin receptor targeted and non-targeted
particles accumulated in the same amounts at the tumour site, but intracellular delivery is
seen only in the targeted vesicles112. Many other ligands have been assessed to target
cancer-related markers including: fibroblast growth factor receptors113; HER2114; and the
folate receptor (FR)115. Folate receptors are the focus of the following section.
1.9 Targeting liposomes via the folate receptor (FR)
Good cancer target candidates should have the following properties: homogenous
expression on all target cells; binding with their ligand should facilitate internalization
(endocytosis); a low degree of "shedding" of target molecules (i.e., release from cells);
and they should play an important role in tumour cell viability such that downregulation
(to avoid targeting) would lead to decreased survival and malignancy116. Many of these
qualities are what make exploiting the FR on cancer cells an attractive strategy. Folic acid
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(FA), an essential vitamin, is required for one-carbon reactions and the synthesis of
nucleotide bases. Cells normally take up physiological levels of FA via the reduced folate
carrier117 or, in some cases, the proton-coupled folate transporter118. Fortunately, neither
of these transporters have an affinity for folate conjugates, so folate-functionalized
particles are left to interact with FRs expressed on a select few cell types. Depending on
the source of FR-expressing cells, 4 or 5 different FRs have been described. For the
purposes of this study only FR-α (FOLR1) will be explored, although it is noteworthy
that FR-β can be found on the surfaces of macrophages and hematopoietic
malignancies119. FR-α is 38-44 kDa glycosyl phosphatidylinositol-(GPI-)anchored
membrane protein normally found on the apical surfaces of many epithelial cells,
where it would be inaccessible to intravenously administered folate therapies. It is
constitutively overexpressed in many human cancers, especially those of ovary,
cervix, endometrium, lung, kidney, breast, colon and brain origin120. In normal cells,
proliferation is inversely correlated with FR expression and positively correlated
with extracellular folate concentrations (EFC), since the EFC inversely regulates FR
levels121. Therefore, it is believed that FR expression in many cancer types has
arisen to allow for greater competition for the minimal folate concentrations (~2 x
10-8 M) found in extracellular fluids122. It is difficult to directly assess the exact
number of FR’s per cell, however, studies using radiolabeled folic acid derivatives
indicate binding can range from 1-4 pmol/106 cells within the first 30 m depending
on the cell type123,124. Upon binding with FA, the FR becomes internalized and brings
FA or any FA-conjugated particles along with it, which is a good trait for a target.
There does seem to be a debate on the fate of the folate conjugates, as monovalent
folate particles (internalized via a single FR) are believed to cycle back to the plasma
membrane after forming early endosomes, while multivalent folate conjugates
(internalized via multiple FRs; i.e., liposomes, nanoparticles) are trafficked to late
endosomes and lysosomes for degradation right away125. This needs to be
considered when using FR-targeting liposome particles, but also offers an advantage
as the late endosome pathway has a pH of around 5.0 that may be exploited by pH–
triggered molecules126. Another advantage of using the FR is that its ligand folate is a
small, non-toxic molecule with low immunogenicity that binds to the FR with a high
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affinity (Kd = 0.1 nM) even after being modified at it carboxyl end to permit lipid
anchoring, making it a suitable conjugate for many particles127.
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Objectives and Hypothesis
The purpose of this project is to test the capacity of a folate receptor (FR)targeting liposome to deliver thymidylate synthase (TS) siRNA to the cytosol of FRpositive cancer cells where it can activate the RNAi machinery. We first hypothesize that
non-targeting liposomes will mediate siRNA uptake into cells more efficiently than
naked siRNA alone. We further hypothesize that decoration of siRNA/liposome
complexes with folate will enhance their capacity to deliver siRNA to FR-positive human
tumour cells both in vitro and in vivo, as a strategy to increase antisense effectiveness.
We test these hypotheses through three objectives. Firstly, we characterize the liposomes
based on their siRNA encapsulation yield, particle stability and size, and ability to protect
against serum nucleases. Next, we determine transfection efficiencies (cellular uptake) in
vitro, and organ/tissue distribution of siRNA/liposome complexes following systemic
administration in vivo. Finally, we assess the ability of the siRNA/liposomes to knock
down their gene targets both in vitro and in vivo.
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Chapter 2

2

Materials and Methods

2.1 Cell culture
Cell lines shown to have various levels of folate receptor expression120 were chosen
for experimentation. KB (human HeLa cell variant, cervical adenocarcinoma), A549
(human adenocarcinoma), HeLa (human cervical carcinoma), OVCAR-3 (human ovarian
adenocarcinoma), B16-F10 (mouse melanoma) cell lines were acquired from the
American Type Culture Collection (ATTC). KB, HeLa and B16-F10 cells were gown in
Dulbecco’s modified Eagle’s medium (DMEM)(GIBCO, Carlsbad, CA, USA) containing
10% (v/v) heat-inactivated fetal bovine serum (FBS). A549 cells were maintained in
Minimum Essential Medium Alpha Medium (AMEM) (GIBCO) supplemented with 10%
(v/v) FBS. OVCAR-3 cells were cultured in Roswell Park Memorial Institute medium
(RPMI) (GIBCO) supplemented with 20% (v/v) FBS. All cell lines were incubated at
37oC in 5% CO2. Cells were typically passaged 1:10 by trypsonization 1-2 times a week
and regularly frozen in 1:10 DMSO:FBS at -80 oC to maintain low passage numbers.
2.2 siRNA sequence design
A 19 nucleotide sequence targeting human TS mRNA (TS siRNA)(coding region
526-544) and a 19 nucleotide control sequence (C2 siRNA with no known target were
synthesized by Dharmacon, Inc. (Lafayette, CO, USA)28. TS siRNA and C2 siRNA were
labeled with Cyanine 3 (Cy3) on the 5’ end of their sense strands, yielding Cy3-TS
siRNA and Cy3-C2 siRNA, respectively. The sequence constructs were: TS siRNA: 5’GGACUUGGGCCCAGUUUAU-3’ (sense) and 5’-AUAAACUGGGCCCAAGUCC-3’
(antisense); C2 siRNA: 5’-UGGUUUACAUGUUGUGUGA-3’ (sense) and 5’UCACACAACAUGUAAACCA-3’ (antisense).
2.3 Materials and preparation of liposome particles
1,3-Dioleoyl-3-trimethylammonium propane (DOTAP), 1,2-dipalmitoyl-snglycero-3-phosphocholine (DPPC), cholesterol, 1,2-distearoyl-sn-glycero-3-
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phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG2000), and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000]
(Folate-DSPE-PEG2000) were purchased from Avanti Lipids, Inc. (Alabaster, AL). All
lipids were dissolved and stored at -20oC in a 9:1 chloroform/methanol solution.
2.3.1 Passive encapsulation protocol
The “passive encapsulation” protocol was characterized by the incubation of siRNA
to the lipid film prior to the extrusion of the liposome particles and for the purposes of
our project was the primary mode of particle synthesis. This differed from the less-used
“lipoplex” protocol where siRNA was added to the fully formed liposomes following
extrusion (discussed below). Using the “passive encapsulation” protocol, folate receptortargeting liposomes were constructed using one of two separate methods: the “folate
before” method or the “folate after” method. In the “folate before” method DOTAP,
DPPC, cholesterol and Folate-DSPE-PEG2000 (at lowest concentration) were mixed in a
1:3.5:3.5:0.018 molar ratio and evaporated to complete dryness under vacuum, forming a
lipid film. The lipid film was hydrated using a TS (fol-lip-TS siRNA) or control (fol-lipC2 siRNA) siRNA/protamine mixture at a molar ratio of 30:0.0037:1
DOTAP:protamine:siRNA and incubated at 50-60oC for 10 min to form large
multilamellar liposome-siRNA/protamine complexes in solution. The multilamellar
liposome solution was then rigorously vortexed and sonicated for 2-5 m at 50-60oC in a
bath sonicator. The sonicated solution was extruded sequentially through polycarbonate
membranes of decreasing pore size (0.2 and 0.1 mm diameter pores). The resultant small,
unilamellar liposome solution was kept at 50-60oC until it could be transfected into cells.
The “folate after” method followed the same protocol as above with the exception that
Folate-DSPE-PEG2000, in the same molar ratio, was added to the extruded unilamellar
liposome solution following extrusion instead of to the lipid film. The liposomes and
Folate-DSPE-PEG2000 were allowed to incubate for 1-2 h to allow folate integration. To
construct the non-targeting (non-fol-lip-C2 siRNA or non-fol-lip-TS siRNA) liposomes,
the above protocol was followed aside from the incorporation of Folate-DSPE-PEG2000 to
the liposome solution. When an experiment called for PEGylated liposomes, DSPEPEG2000 was added to the extruded liposome solution in a molar ratio of 1:0.22
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DOTAP:PEG for folate and 1:0.23 DOTAP:PEG for non-folated liposomes, respectively.
2.3.2 Lipoplex protocol
Folate decorated (fol-lip) and non-targeting (non-fol-lip) particles were synthesized
in a similar fashion according to the “passive encapsulation” protocol (above), with the
difference that the lipid film layer was hydrated with RNase-free water alone prior to
extrusion. Following extrusion, the small unilamellar particles were lyophilized (freezedried) and stored at -20oC. This allowed for stable storage of the liposomes until needed.
Upon use, the liposomes were re-hydrated with RNAse free water. A selected amount of
siRNA was then added to the re-hydrated liposomes and incubated for 20 m to allow for
the negatively charged siRNA to electrostatically complex with the positive liposomes.
2.4 In vitro assessment of lipsome-Cy3 siRNA uptake using flow cytometry
Cells (KB, A549, HeLa, OVCAR-3 or B16 F10) were seeded in either 6 or 12 well
Falcon tissue grade plates at concentrations ranging from 1-2 x 105 cells/well depending
on the experiment. Two h prior to transfection the media was replaced with either folatefree RPMI or 1 mM folate RPMI depending on the experiment. Twenty four h after
seeding the cells were with incubated with either non-fol-lip-Cy3-C2 siRNA or fol-lipCy3-C2 siRNA to assess the difference in uptake based on FR targeting. Initially, both
non-fol-lip-C2 siRNA and fol-lip-C2 siRNA were used as controls. However, they did
not yield significant differences in background Cy3-positivity from a non-treated control
(NTC). In general, media was aspirated and cells washed with phosphate-buffered saline
(PBS) 4 h after addition of liposomal preparations (and at different times under
circumstances where incubation times were varied) before being replaced with fresh
media. The cells were then trypsinized and resuspended in 250-300 μl of PBS prior to
analysis by flow cytometry.
2.5 Confirmation of lipsome-Cy3 siRNA uptake in vitro by fluorescent microscopy
Cells were seeded in plates according to the same protocol described above (section
2.4). Twenty four h after seeding the cells were incubated with either non-fol-lip-Cy3-C2
siRNA or fol-lip-Cy3-C2 siRNA. Twenty four h following addition of liposomal
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preparations, media was removed and cells were rinsed (2x) with PBS and replaced with
fresh media to remove any excess liposome particles in the media. The cells were then
imaged using by fluorescent microscopy.
2.6 Assessment of TS silencing in vitro using lip-Cy3-TS siRNA
2.6.1 RNA extraction
Cells (KB and A549) were seeded in plates according to the same protocol
described above (section 2.4). Twenty four h after seeding the cells were incubated with
TS targeting non-fol-lip-Cy3-TS siRNA or fol-lip-Cy3-TS siRNA. Non-fol-lip-Cy3-C2
siRNA and fol-lip-Cy3-C2 siRNA were used as negative controls. Twenty four or 48 h
following transfection, the cells were washed twice with PBS and harvested using TRIzol
(Invitrogen, Carlsbad, CA, USA) for RNA isolation. Chloroform (Bioshop, Burlington,
ON, CA) was added to the cell-TRIzol solution and phase separation through
centrifugation allowed for RNA purification and extraction in the top aqueous layer.
RNA was then precipitated out of solution using isopropanyl (Bioshop). The RNAisopropanyl solution was centrifuged to form a RNA pellet before the isopropanyl was
decanted. The RNA pellet was then suspended (2x) in 75% ethanol to remove any
impurities (excess salts and proteins). The 75% ethanol solution was removed and the
RNA pellets were dried for 30 m. Any remaining liquid was removed using an
autoclaved Q-tip. The remaining RNA pellet was re-suspended in 20 ul of RNAse free
water. RNA was quantified using Nanodrop’s ND-1000 Spectrophotometer (Wilmington,
DE, USA)). RNA quality (degradation) was assessed on a 1% agarose gel run at 50V for
20-40 m and imaged using Bio-rad’s Gel Doc (Mississauga, ON, CA).
2.6.2 Reverse Transcription
RNA (1 ug per reaction vessel) was then reverse-transcribed (RT) using Moloney
Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) in the presence of dNTPs,
random primers and DDT. The RT reaction was carried out under the following
conditions:

37

Table 2.1. Reverse Transcription reaction cycle parameters
Temperature (oC)

Duration (h)

Function

25

00:10:00

Primer attachment

37

1:00:00

Polymerization

4

00:05:00 (+ HOLD)

Prevent degradation

The synthesized complimentary DNA (cDNA) was stored at -20oC until it was needed for
quantitative PCR (qPCR).
2.6.3 Quantitative PCR
cDNA (1 μl) was used per reaction vessel (50 ng cDNA assuming 100% RT
reaction). qPCR reactions used TaqMan Gene Expression Master Mix (Applied
Biosystems, Foster City, CA) in an Applied Biosystem’s ViiA7 qPCR machine. The TS
specific forward and reverse primers were purchased from Applied Biosystems and used
at a final concentration of 600 nM. The primer sequences for human TS were: 5’GGCCTCGGTGTGCCTTT-3’ (forward) and 5’-GATGTGCGCAATCATGTACGT-3’
(reverse). A TaqMan MGB probe labeled with 6-FAM (Applied Biosystems) was used at
a concentration of 200 nM. It had a sequence of 5’-6-FAMAACATCGCCAGCTACGCCCTGCMGBNFQ-3’. A pre-designed human GAPDH
labeled with FAM and MGB probe (Applied Biosystems) was used as an endogenous
control. All individual samples/controls were run in triplicate in a 384 well plate.
Standard curves (when applicable) were constructed from one of the unknown samples
using a dilution series ranging from 1000 to 15.6. The parameters of the qPCR run are
shown below:
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Table 2.2. Quantitative PCR cycle parameters
Temperature (oC)

Duration (m)

Function

50

02:00

Optional

95

10:00

Initial denaturation/
polymerase activation

95

00:15 (40 cycles)

Denaturation

60

01:00 (40 cycles)

Primer alignment and
polymerization

qPCR results were analyzed in the Life systems software using one of two methods:
ΔΔCT method or the standard curve method. The ΔΔCT method was primarily used when
comparing several treatment groups to the same control, thus yielding relative quantities,
while the standard curve method helped to verify amplification and overall qPCR
reaction efficiencies and assess statistical significance between groups (further explored
in the Discussion section)128.
2.7 Liposome particle size and zeta potential
Folate decorated (fol-lip-Cy3-C2 siRNA) and non-targeting (non-fol-lip-Cy3-C2
siRNA) liposomes were prepared according to our protocol. The particles were diluted in
RNAse-free water and mean particle diameter and surface charge (zeta potential) was
assessed using a Zetasizer Nano Series instrument (Malvern Instruments Ltd., UK)
according to the manufacturer’s protocol. The instrument counts approximately 200,000
particles/second until a stable reading is obtained. Particle size was measured over
several time points to investigate particle aggregation and overall stability over time.
2.8 Liposome:siRNA binding capacity assay
Lyophilized aliquots of PEGylated liposomes synthesized according to the
“lipoplex” protocol were re-hydrated in 200 μl of RNAse-free water. Varying siRNA
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quantities were added to the re-hydrated liposomes yielding liposome:siRNA molar
weight ratios of 35, 30, 25, 20, 15, 10. Following a 20 m incubation, the PEGylated
“lipoplex” lip-Cy3-C2 siRNA mixtures were run on a 1% agarose gel at 50 V for 30-40
m and imaged using a Biorad imaging system.
2.9 Nuclease degradation assay
Folate decorated (fol-lip-Cy3-C2 siRNA) and non-targeting (non-fol-lip-Cy3-C2
siRNA) PEGylated liposomes were synthesized according to the “passive encapsulation”
protocol. Liposomes were aliquoted into 1.5 mL centrifuge tubes yielding approximately
0.71 nM of siRNA (before extrusion) per timepoint (0, 1, 2, 4, 8, 24, 48 h). The liposome
aliquots were then incubated in a 1:1 (v/v) ratio with FBS (contains serum nucleases).
Samples were incubated at 37oC (0 h) and transferred to -80oC at their specific timepoint
to halt plasma nuclease activity. Free Cy3-C2 siRNA in mouse plasma was used as a
positive control. Following the final timepoint, samples were thawed at room temperature
and siRNA was extracted according to the TRIzol RNA extraction protocol described
previously. Following suspension in RNAse free water, siRNA quantities were measured
using the ND-1000 Spectrophotometer (Nanodrop). Equal amounts of siRNA were mixed
with 6 x loading buffer (Table 2.3) and run on a 15% acrylamide TBE-PAGE gel at 80V
for 1.5 h. The gels were incubated in ethidium bromide (50 μg/mL) for 8-10 m and
imaged using Bio-rad’s image doc.
Table 2.3. Recipe for 6x loading buffer used in assessing siRNA degradation
Amount

Reagent

3 mL

100% Glycerol

3 mL

0.5 M EDTA

3 mg

Bromophenol blue

3 mg

Xylene cyanol

4 mL

Sterile water
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2.10 Ribogreen siRNA quantification assay
siRNA concentration in liposomes was quantified using the Quant-iT RiboGreen
RNA kit (Invitrogen) according to their protocol. A high-range standard curve (assay
points: 0 ng/ml, 20 ng/ml, 100 ng/ml, 500 ng/ml and 1 μg/ml) was constructed from a
dilution series of 2 μg/ml siRNA stock solution. Liposomes were constructed according
to the “passive encapsulation” and “lipoplex” protocols above, with the difference that
siRNA was not incubated with protamine prior to addition to the lipid film layer as it
prevented RiboGreen dye binding to siRNA. Liposome samples were diluted with TE
buffer (10mM Tris-HCl, 1 mM EDTA, pH 7.5) over a range of 0.1 to 0.01 of the original
sample concentration to fall within the standard curve. The diluted samples were
incubated in a 1:1 (v/v) ratio with Quant-iT RiboGreen working solution for 10 m and
read in a fluorescent microplate reader (490 nm excitation, 525 nm emission).
2.11 Folic Acid inclusion assay
According to the “passive encapsulation” protocol, folate-decorated liposomes were
synthesized by both the “folate before” and “folate after” methods. No siRNA/protamine
mixture was added during synthesis as it interfered with the absorbance readings of folate
ligand. A standard curve was created using a dilution series of free Folate-DSPE-PEG2000
in RNAse free water. Absorbance readings were taken at 285 nm using a UV-Vis
spectrophotometer (Beckman Coulter, Mississauga, Ontario)
2.12 Mouse Models
NIH-III nude mice (6-8 week old females) were purchased from Charles River
Laboratories International, Inc. (Wilmington, MA). Mice were maintained under a
pathogen-free environment in the Victoria Hospital barrier facility. All experiments were
conducted in accordance with the standard operating procedures set forth by the Canadian
Council on Animal Care and Western University Animal Use Subcommittee.
2.13 FR expression of cultured cells using flow cytometry
KB, A549, HeLa, and OVCAR-3 cells were plated at a concentration of 2 x 105
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cells/T25 flask. Twenty four h after plating, media was aspirated and 1 ml of 10 mM
EDTA was added to each flask. They were then incubated at 37oC for 10-15 m or until
most of the cells could be seen detached under the microscope. Four ml of fresh media
was added to each flask and the contents were dispensed into appropriate flow cytometry
vials. Samples were centrifuged at 12,000 rpm for 8 m and washed with fresh PBS.
Following re-centrifugation the PBS was decanted and primary monoclonal mouse IgG1
FOLR1 or isotype antibody (R & D Systems, Inc., Minneapolis, MN) was added to each
sample (2.5 ug/106 cells). Cells were incubated in primary antibody (1o ab) for 30-40 m at
4oC. Samples were then centrifuged and washed again in PBS to remove any unbound
antibody. Eight μl of phycoerythrin-conjugated anti-mouse IgG secondary antibody (IgGPE 2o ab)(R & D Systems) was added to each sample and incubated in the dark for 30 m
at 4oC. Cells were then washed again with PBS and resuspended in 300 μl of PBS for
analysis by flow cytometry.
2.14 FR expression in vivo and in vitro, assessed by immunoblot
2.14.1 Tissue harvesting/protein extraction
NIH-III mice were subcutaneously inoculated with 2 x 106 KB cells. Tumours were
measured twice per week with hand calipers (Mitutoyo, Kawasaki, Japan) and mice were
sacrificed when tumour volumes reached approximately 600 mm3. Tumour tissue was
extracted, placed on dry ice and stored at -80oC until needed. A small (<0.5 g) sample of
tumour was excised and suspended in 150 ul of cell lysis buffer (see Table 2.4 for recipe).
The solid tumour tissue was disrupted using a hand homogenizer until it was evenly
distributed throughout the lysis buffer. To process cells grown in vitro for immunoblot,
cells were plated at 2 x 105 cells/T25 flask and removed from the flask mechanically
using a cell scraper 24 h after seeding. One hundred and fifty μl of cell lysis buffer was
added to each cell pellet. Both in vivo and in vitro samples were processed following the
same protocol from this point forward. Samples were placed on ice for 20 m with
vortexing every 5 m before being centrifuged at 12,000 g for 10 m (4oC). The protein
containing supernatant was collected and kept on ice.
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Table 2.4. Sample lysis buffer for immunoblot
Amount

Reagent

0.88 g

NaCl

2 mL

1M Tris-HCl (pH 7.6)

1 mL

10% SDS

1 mL

Triton X-100

500 ul

0.2M EDTA

100 mL

Deionized water

2.14.2 Protein quantification
Total protein content was quantified using a Bradford Assay. A standard curve was
constructed using a dilution series from a 10 mg/mL working solution of bovine serum
albumin (BSA). Samples were diluted in PBS (1:350) and diluted (6:4 reagent:PBS)
Bradford reagent was added to each sample. Each sample was then distributed in 3 wells
of a 96 well plate and read on a fluorescent microplate reader. Protein quantities were
determined from the standard curve.
2.14.3 Gel electrophoresis and protein transfer
Separate gels were required to detect FOLR1 and endogenous control protein actin
due to their similar size and the FOLR1 antibody requiring non-reducing conditions.
Samples were mixed 1:1 (v/v) in 2x sample loading buffer (see Table 2.5 for recipe) and
actin samples (reducing conditions) were heated at 90oC fro 5 m prior to gel loading. A
20% acrylamide gel was used as it yielded the cleanest protein bands. Ten μg and 25 μg
of protein suspended in a total volume of 35 ul were loaded into each well for FOLR1
and actin detection, respectively. Following sample loading the gels were run at 120 V
for 1 h 40 m in a standard Bio-rad gel electrophoresis apparatus. After the allotted time,
the gels were removed and the area containing the assessed proteins were excised from
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the gel and placed in transfer buffer along with the nitrocellulose film. A “transfer
sandwich” was constructed and the transfer apparatus was run on 100 V for 1 h at 4oC.
Table 2.5. Recipe for 2x sample loading buffer
Amount

Reagent

3.05 mL

Deionized water

1.25 mL

0.5 M Tris-HCl (pH 6.8)

3 mL

100% Glycerol

2 mL

10% SDS

0.2 mL

0.5% Bromophenol blue

Store in 950 ul aliquots at -20oC
50 ul (added to 950 ul aliquot before use)

2-Mercaptoethanol

2.14.4 Blocking, antibody labeling and imaging
The nitrocellulose membrane was removed from the “transfer sandwich” and
blocked with 5% skim milk for 1 h. The paper was then washed several times in TBS-T
(15 m, 5 m, 5 m) before being incubated with either primary monoclonal mouse IgG1
anti-FOLR1 antibody(1:1000)(R & D Systems) or polyclonal rabbit IgG1 anti-β actin
antibody(1:2000)(Santa Cruz Biotechnology, Dallas, Texas) in 1% skim milk for 1 h. The
nitrocellulose film was washed in TBS-T several more times (15 m, 10 m, 10 m) to
remove unbound primary antibody. The nitrocellulose film was then incubated with
secondary antibody (when detecting FOLR1, 1:2000 anti-mouse-horse radish peroxidase
[HRP],GE Healthcare UK Limited, Little Chalfont Buckinghamshire, UK) and, when
detecting β actin, 1:10,000 anti-rabbit-HRP (GE Healthcare UK Limited) in 1% skim
milk for 45 m. The nitrocellulose film was then washed again several times in TBS-T (15
m, 5 m, 5 m) before being blotted with filter paper. Approximately 1 ml of HRP substrate
(GE Healthcare UK Limited) was added to each nitrocellulose film fragment for 1-2 m,
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and then blotted away using filter paper. The proteins to be detected were then imaged
using a 860 Storm scanner (Molecular Dynamics, Baie d’Urfe, Quebec).
2.15 In vivo distribution of Cy3 siRNA using folate receptor-targeting liposomes
Non-targeting (non-fol-lip-Cy3-C2 siRNA) and folate decorated (fol-lip-Cy3-C2
siRNA) liposomes were synthesized according to the “passive encapsulation” protocol.
Non-targeting or FR-targeting liposomes were injected into tail veins of NIH-III mice
bearing two KB xenografts (one in each flank) of approximately 600 mm3 each. The
amount of Cy3 C2 siRNA used was 50 μg/mouse prior to extrusion. There were 3 mice
per treatment group. Mice were sacrificed 6 h following injection and various tissues
(tumour, heart, skin, kidney, liver, muscle, connective tissue and intestine) were collected
and placed in cryostat holders (Tissue-Tek, Torrance, CA, USA) and suspended in OCT
(Tissue-Tek) and stored at -80oC. The cryostat samples were then sectioned in 10 um
sections using a cryostat (Leica Biosystems, Concord, Ontario) and mounted on glass
slides for fluorescent microscopy.
2.16 In vivo silencing of TS using folate receptor-targeting liposomes
Non-targeting (non-fol-lip-Cy3-TS siRNA) and folate decorated (fol-lip-Cy3-TS
siRNA) liposomes were synthesized according to the “passive encapsulation” protocol.
Folate decorated liposomes containing C2 siRNA (fol-lip-Cy3-C2 siRNA) were used as a
negative control. NIH-III mice were inoculated subcutaneously in two areas on their
backs with 2 x 105 KB cells/inoculation. Liposomes were injected into tail veins of NIHIII mice (50 μg/injection before extrusion) 2 days following KB tumour inoculation and
thereafter once per week for a total of 4 injections. There were 6 mice per treatment
group. Mouse body mass was monitored twice a week and tumour size was evaluated
twice a week using calipers. Twenty four h following the final treatment, the mice were
euthanized and tumour tissue was harvested and stored at -80oC.
Several days later, the tumour tissue was thawed and a small amount (<0.2 g) was
analyzed by qPCR for specific RNA levels. Tumour tissue was placed in TRIzol
(Invitrogen) for RNA isolation and completely disrupted using a hand homogenizer.
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From this point the protocol used for analyzing in vitro target mRNA reduction was
followed (above, section 2.6.1).
2.17 Statistical analysis
Data is presented typically as means ± standard deviations. Differences between
experimental groups were analyzed using a Student’s t test Test and differences with p
values less than 0.05 (confidence limit selected a priori) were considered to be
significant.
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Chapter 3

3

Results

3.1 Characterization of the liposome particles
3.1.1 Liposome surface charge (zeta potential) and size as determinants of
particle stability
A common indicator to determine a nanoparticle's overall stability in solution is to
measure its zeta potential. Nanoparticles with an overall net charge will attract oppositely
charged ions to its surface, forming a Stern layer. As the particle moves in solution an
electrostatic potential is created between the two layers, which is called the zeta potential
and is directly related to the surface charge of the particle129. The zeta potential of both
non-targeting and folate-decorated liposomes with folate added either before (“folatebefore”) or after (“folate-after”) the extrusion process was measured either alone or in the
presence of siRNA (Table 3.1). An example of a typical readout of zeta potential can also
be seen in Figure 3.1. As expected, the zeta potentials are all positive since the liposomes
contain cationic lipids. The zeta potential increased in the non-targeting liposomes when
no siRNA was present, since siRNA carries a net negative charge from its phosphodiester
backbone. Surprisingly, the same was not observed with the “folate before”-decorated
liposome. This may have resulted from a lack of siRNA entrapment by the liposome
particle or differences in the amount of folate-DSPE that integrated into the liposomes
(discussed below). The folate-DSPE molecule carries a net charge between -1 and -2
depending on the aqueous environment. In an attempt to balance the surface charges of
the non-targeting and folate decorated liposomes, PEG, which contains an overall net
charge of -1, was added to the non-targeting liposomes. It is difficult to be exact,
however, due to the protonating nature of the folate-DSPE molecule. Unexpectedly, the
"folate after" liposomes had a slightly higher zeta potential, which is likely influenced by
the small sample size and amount of siRNA that had been included following the
extrusion process. Regardless, a zeta potential around +30 or greater is considered
strongly cationic and lead to relative stability129.
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Table 3.1. Zeta potentials of various liposome particle mixtures. Non-targeting (nonfol) and FR-targeting (fol) liposomes with folate inserted either prior to (fol before) or
following the extrusion process (fol after) were synthesized in the presence (+siRNA) or
absence (-siRNA) of siRNA. Samples were diluted 1:10 in water and analyzed for size
and charge using the Malvern Zetasizer. Legend: N – is number of individual
experiments; n – number of individual samples.
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Sample

Zeta Potential (mV)

Sample size

Non-fol-Cy3-C2RNA
(+siRNA)

29.42 ± 2.53

N = 3; n = 9

Non-fol-Cy3-C2RNA
(-siRNA)

42.8 ± 3.88

N = 2; n = 6

Fol-Cy3-C2RNA (fol
before)(+siRNA)

26.7 ± 5.72

N = 2; n = 6

Fol-Cy3-C2RNA (fol
before)(-siRNA)

27.07 ± 1.34

N = 1; n = 3

Fol-Cy3-C2RNA (fol
after)(+siRNA)

36.7 ± 1.55

N = 1; n = 3
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Figure 3.1. Example of zeta potential readouts for liposome samples. Liposomes were
synthesized according to the “passive encapsulation” protocol and kept at ~55oC until the
measurements were performed soon after synthesis. Samples were diluted 1:10 in water
and analyzed for size and charge using the Malvern Zetasizer. A) Zeta potential profile
for non-fol-Cy3-C2RNA; B) zeta potential profile for fol-Cy3-C2RNA.
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Another important attribute of a nanoparticles is size (diameter). As described
above, smaller sizes (< 200 nm) are preferred for effective exit from the blood stream and
entry into extracellular space, and enhanced uptake especially through the interstitial
tissue in vivo104. A measure of particle size change over time is also an indicator of a
particle’s overall stability. Zeta potential is the primary indicator of stability. However,
changes in particle size can show how long the particles last in solution before becoming
unstable and aggregating to form larger particles with less capacity to be taken up by
cells. Examples of stable and aggregating particles as well as particle stability over time
can be seen in Figure 2. Looking at the particle size readouts, a single normal distribution
can be seen up until the 6 h time point indicating good particle stability (Figure 3.2A). At
the 12 h time point, some aggregation has taken place as a distinct peak can also be seen
at a size >1000 nm (Figure 3.2B). A particle stability >6 h is important because in some
cases it could be several hours from the time of synthesis before the particles are
transfected into cells or injected in mice, where a relatively homogenous liposome
mixture is ideal. The sizes of the non-targeting and folate-decorated liposomes are
similar, which is an important aspect to consider when comparing the two groups in vitro
(sedimentation effect) and in vivo (RES entrapment and EPR effect).
3.1.2 Folic acid decoration on liposome
A primary goal was to assess differences in cellular uptake between non-targeting
and folate-decorated liposomes in FR-positive and FR-negative cell lines. Therefore, the
actual amount of folate-DSPE that was incorporated into liposomes was considered.
Folate was either added to the liposomes according to the “folate before” or “folate after”
protocols. Absorbance readings at 285 nm indicated that 3.92-9.16% and 9.56 ± 0.34%
(N=2) of folate-DSPE successfully integrated into the liposomes using the “folate before”
and “folate after” synthesis protocols. This was not as high as reported in the literature
(see Discussion section) and may have had an impact on experiments described below.
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Figure 3.2. Liposome particle size and stability over time. Liposomes were
synthesized according to the “passive encapsulation method” and assessed for size and
charge using the Malvern Zetasizer. Liposome solutions were kept at ~ 55oC until the
specific time point. A) Size distribution profile of fol-Cy3-C2RNA (+PEG) liposomes
immediately after synthesis; B) size distribution profile of fol-Cy3-C2RNA (+PEG)
liposomes 12 h following synthesis; C) liposome particle stability over a 12 h period with
vertical bars displaying the size range.
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3.1.3 siRNA binding/encapsulation yield
Another important property of liposome particles is their capacity to interact with
siRNA. This would include siRNA electrostatically interacting with the cationic lipids or
being encapsulated during the extrusion process. Liposome particles were synthesized
using one of two methods: the “passive encapsulation” protocol (see Materials and
Methods, Section 2.3.1) and the “lipoplex” protocol (see Materials and Methods, Section
2.3.2).
In the “lipoplex” protocol, liposomes were first synthesized alone and then siRNA
was added after. In this case it was valuable to know how much siRNA a given amount of
lipid was capable of binding. To assess this, liposome:siRNA complexes with different
mass ratios (i.e., different amounts of siRNA associated with liposomes) were incubated
and separated by agarose by gel electrophoresis (Figure 3.3). SiRNA disassociated from
liposomes has high electrophoretic mobility, and visualization of that highly mobile
siRNA was a measure of the capacity of liposomes to encapsulate the nucleic acids.
Wells containing various amounts of free siRNA were included for reference. This is an
indirect measure of binding ability since the bright white bands depict unbound siRNA.
Liposome-bound siRNA remains in the wells (at the top of the photograph). It appears
that a residual amount of free siRNA remained unbound regardless of the amount added.
This could be due to the presence of negatively charged PEG molecules present on the
surface of the liposomes. The amount of unbound siRNA increased at liposome:siRNA
molecular mass ratios of 15 to 10 and this set the upper limit of the liposome-siRNA
binding capacity at 12:7.2 DOTAP:siRNA molar mass using the “lipoplex” method.
Therefore, during the course of experimentation, values below this threshold were used.
The above method was used to qualitatively determine the amount of siRNA the
liposomes could bind. However, a quantitative method would be more useful, especially
one that could differentiate siRNA on the inside or outside of the liposomes. Therefore,
RiboGreen dye was used to detect siRNA. RiboGreen fluoresces when bound to free
siRNA, with the advantage that it differentiates between siRNA bound to the interior or
exterior of the liposome since the lipid bilayer is impermeable to the dye, which can
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Figure 3.3. Qualitative measurement of the siRNA binding capacity of liposomes
synthesized using the “lipoplex” method. Liposome solutions were aliquoted into
uniform amounts and then incubated for 20 m with various amounts of siRNA creating
the following liposome:siRNA molar mass ratios of 35, 30, 25, 20, 15 and 10. The
samples were then run on a 1% agarose gel. The white bands indicate unbound siRNA.
Wells containing siRNA only (0.34, 0.48 and 1.20 μg) were included for reference.
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interact with interior siRNA only when the liposome:siRNA complex is treated with a
surfactant (i.e., Triton X-100) to release interior nucleic acid. Liposomes were
synthesized according to the “passive encapsulation” and “lipoplex” protocols and
incubated with RiboGreen working solution in the presence or absence of Triton X-100.
RiboGreen fluorescence measurements were used to determine the percentage of total
siRNA entrapped by the liposomes (bound on either interior or exterior) and percentage
of total siRNA encapsulated by the liposomes (interior only)(Table 3.2). Several
amendments to our protocol were necessary, as we found that RiboGreen dye could not
bind siRNA complexed with protamine (data not shown). This made quantification of
siRNA encapsulation possible only in material produced by a protocol that approximated,
but did not exactly reproduce the “passive encapsulation” synthesis protocol.
Furthermore, it appears that RiboGreen cannot bind siRNA well when it electrostatically
interacts with an intact liposome (Table 3.2). This became evident as the percentage of
siRNA encapsulated following extrusion was 80 and 86% for the “lipoplex” and “passive
encapsulation” protocol, respectively, when theoretically the maximum amount of siRNA
that should occur on the interior from the passive encapsulation protocol is 50% and, in
the lipoplex method, much less because the siRNA is added to the exterior of preformed
liposomes. Therefore, it is hypothesized that the RiboGreen assay can accurately quantify
only the total amount of siRNA entrapped by the liposomes, determined following lysis
of the liposome:siRNA complex.
3.1.4 Ability of liposomes to protect siRNA from serum nucleases
Ultimately, liposomes must protect and deliver siRNA to target organs and cells
in vivo. As mentioned previously, this includes protecting the siRNA payload against
serum nucleases that can degrade the siRNA and destroy its antisense function. To test
the ability of both non-targeting and folate-decorated liposomes to protect siRNA against
serum nucleases, aliquots of liposome-siRNA synthesized using the “passive
encapsulation” protocol were incubated in FBS in a 1: ratio (v/v) and separated using a
15% acrylamide TBE-PAGE gel (Figure 4). The presence of bands indicates intact
siRNA. Degraded siRNA was removed during siRNA purification; was of high
electrophoretic mobility (due to small size of degradation products) and did not
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Table 3.2. Quantification of liposome-siRNA interaction determined by the
RiboGreen assay. Liposome-siRNA solutions were either treated with RiboGreen
working solution alone (intact liposomes) or in the presence of 10% Triton X-100 (lysed
liposomes). Lysed readings were used to determine the amount of siRNA on the interior
of the liposomes and the combination of intact and lysed readings determined the total
amount of siRNA entrapped.
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Lipoplex method

Passive encapsulation
method

Percentage of total siRNA

94.2 ± 9.5

49.4 ± 3.42

76.0 ± 8.1

43.7 ± 2.96

80.68 ± 2.90

86.05 ± 3.03

entrapped
Percentage of total siRNA
encapsulated
Percentage of siRNA
encapsulated after extrusion
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appear in the size range of intact siRNA; or was undetectable by ethidium bromide
staining due to small size. Figure 3.4 indicates that both the non-targeting liposomes and
the folate-decorated liposomes can protect siRNA up to 48 hours, while the naked siRNA
begins to degrade at 4 h. This is a critical consideration to allow sufficient time for
liposome:siRNA complexes to accumulate at tumour sites.
3.2 Assessing folate-FR-mediated uptake in FR-expressing cell lines, and tissue/organ
distribution following systemic administration in mice
3.2.1 FR expression in various cell lines and xenografts
To determine whether decorating liposomes with folate to target FR on cells
enhances cellular uptake over non-targeting particles, the FR l (folate receptor 1) level on
cells was first determined. Multiple cell lines were tested by incubating cells with a
FOLR1 monoclonal antibody and subsequent secondary antibody conjugated to
phycoerythrin (PE), which could be detected by flow cytometry (Figure 3.5). These data
indicate that the KB cell line possessed the highest level of FR expression with >95% of
cells showing FR positivity and a mean fluorescence intensity (MFI), a measure of the
average fluorescent on a per cell basis, over fourfold higher than the cell line with the
next highest FR MRI (HeLa). Both HeLa and OVCAR-3 cells displayed moderate FR
levels, with approximately 50% of cells being FR-positive. A549 cells had the lowest FR
level, with less than 5% cells of cells positive for FR and a negligible MFI. This wide
spectrum of FR expression across the various cell lines provided a powerful diagnostic
system to investigate the impact that targeting the FR had on cellular uptake. The high
FR-expressing cell line KB (FR++)(Figure 3.5) was selected to investigate folate-FR
mediated uptake. Because of the very low FR levels in A549 (FR-) cells (Figure 3.5),
they were selected as a control for comparison to assess the capacity of FR status to
predict differences in folate-mediated uptake of liposomally-encapsulated siRNA
between cell lines, and provided a suitable negative control to account for factors
independent of FR. The cell lines were evaluated for siRNA uptake in the presence of
either folate-complete media or folate-depleted media (the latter induced by replacing
folate-complete medium 3 hours prior to assessment, and the former maintained by
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Figure 3.4. siRNA integrity following serum nuclease incubation. Non-targeting and
folate-decorated liposome:siRNA complexes synthesized using the “passive
encapsulation” method, or naked siRNA without liposomes, was incubated in a 1:1 (v/v)
ratio for 1, 4, 8, 24, or 48 h. siRNA was then extracted from samples using the standard
RNA extraction method and separated by electrophoresis in a 15% acrylamide TBEPAGE gel. The presence of bands indicates intact siRNA.
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Figure 3.5. Folate receptor levels in various cell lines (determined by flow
cytometry). Cells were cultured in 6 well plates for 24 hrs and then exposed to either
folate-complete or folate-depleted media for 3 h prior to harvesting and incubation with
FOLR1 monoclonal antibody. Next, the cells were incubated with PE-conjugated
secondary antibody and analyzed for PE levels by flow cytometer.
A) Histogram showing representative gating for all cell lines treated with FR primary
antibody and KB cells treated with isotype (control) antibody
B) Percentage of cells positive for FOLR1
C) Mean fluorescence intensity (MFI) of cells (arbitrary value relating to average
fluorescence on a per cell basis).
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replacing medium with fresh medium 3 hours prior to assessment) to determine whether
conditions where the amount of folate unassociated with liposomes would affect FR
levels in target cells. The assessment was predicated on the possibility that that high
unassociated folate in medium would reduce FR levels due to reduced cellular
requirement for folate, and that low medium folate would result in increased cellular
production of FR in response to increased requirement for folate. However, there was no
difference in FR level in cells induced by altering medium folate.
To test the tissue/organ distribution and silencing ability of FR-targeting
liposomes in vivo, KB cells were inoculated into nude mice and grown as subcutaneous
xenografts. Since cells are likely to have different characteristics in vivo than in vitro, FR
level in KB xenografts was confirmed by immunoblot (Figure 3.6). In the data shown in
that figure, KB and A549 cells grown in vitro were included as positive and negative FR
expressers, respectively. KB xenografts and KB cells grown in vitro had similar levels of
FR protein, while the A549 cells grown in vitro did not.
3.2.2 Liposomes enhance siRNA uptake compared to naked siRNA and folate
decoration further enhanced uptake in FR positive cells.
Non-targeting siRNA-loaded liposomes (i.e., no folate) were tested to determine
if they facilitated cellular uptake of control, non-targeting siRNA (C2) compared to
naked C2 siRNA alone (Figure 3.7). For in vivo purposes, it has been reported that
PEGylating liposomes greatly enhances siRNA delivery by inhibiting RES entrapment105,
so the effect of coating liposomes with PEG either directly in the lipid cake prior to
extrusion (+PEG before) or after extrusion (+PEG after) was tested (Figure 3.7). The
non-targeting liposomes showed a significant increase in uptake compared to naked
siRNA (p<0.05) and the inclusion of PEG either before or after had no significant effect
on uptake.
The effect of decorating liposomes with folate to enhance cellular uptake in FRexpressing cells was assessed (Figure 3.8). At first glance, and looking at only the FRpositive KB cells (black bars), it would appear that folate decoration did enhance cellular
uptake by 11.6%. However, there was an unexpected but similar increase (10.3%) in
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Figure 3.6. FR protein expression of KB xenografts. KB cells were grown in culture
and then inoculated in NIH-III nude mice. Upon reaching an average size of 600 mm3,
mice were sacrificed and KB tumours were harvested for immunoblot. Cultured KB and
A549 cells were also included as a reference. Actin protein levels were used as an
internal control and run on a separate gel due to the non-reducing conditions required for
FOLR1 antibody binding.
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Figure 3.7. Percentage of cells positive for Cy3-siRNA after transfection with
PEGylated liposomes or naked siRNA. Non-targeting liposomes encapsulating control,
non-targeting siRNA (C2) were synthesized according to the “passive encapsulation”
protocol and PEG was added either prior to or following extrusion. Liposomes were
transfected in HeLa cells for 4 h before cells were harvested and assessed for siRNA
uptake by flow cytometry.
A) Histogram showing gating of HeLa cells treated with non-fol-Cy3-C2RNA (+PEG
before). 94.6% HeLa cells positive for Cy3-siRNA uptake, 5.44% negative.
B) Percentage of HeLa cells positive for Cy3 siRNA uptake using various delivery
agents.
Naked siRNA – siRNA transfected alone with no delivery agent
non-fol-Cy3-C2RNA (-PEG) – non-targeting liposomes containing no PEG
non-fol-Cy3-C2RNA (+PEG before) – PEG added directly to the lipid cake prior to
extrusion
non-fol-Cy3-C2RNA (+PEG after) - PEG added after extrusion.
One experiment, n=3; *p<0.05 compared to naked siRNA.
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Figure 3.8. Effect of liposome folate decoration on the cellular uptake of Cy3-siRNA.
Non-targeting (no folate) and folate-decorated liposomes encapsulating Cy3-labeled
control, non-targeting siRNA (C2) were synthesized according to the “passive
encapsulation” protocol. Folate was added directly to the lipid film layer prior to
extrusion. FR-positive (KB) and FR negative (A549) cell lines were grown in 6 well
plates for 24 hours and treated with transfected for 4 h before being harvested for flow
cytometry.
A) Histogram showing gating of KB cells treated with fol-Cy3-C2RNA. 61.4% KB cells
positive for Cy3-siRNA uptake, 38.6% negative.
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents. nonfol-Cy3-C2RNA – non-targeting liposomes
fol-Cy3-C2RNA – folate decorated liposomes.
One experiment, n = 3; *p<0.05 compared to naked siRNA in KB cells; &p<0.05
compared to naked siRNA in A549 cells
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siRNA uptake mediated by folate decoration in FR-negative A549 cells (white bars).
These data suggest that the increased uptake of siRNA encapsulated in folate-decorated
liposomes was due to an FR-independent event (possibly mediated by differences in
particle surface charge or the amount of siRNA that was incorporated following
synthesis, since differences can occur among batches).
The next step was to increase the amount of folate added to the liposomes to
determine whether increasing targeting moieties revealed differences in uptake between
cells with low and high FR. Non-targeting, folate-decorated liposomes with the original
amount of folate added (0.81 nmol) and folate decorated liposomes with 3 times more
folate added to the lipid layer (2.42 nmol) were used to treat KB and A549 cells (Figure
3.9). In the KB cell line, the presence of folate on liposomes decreased the fraction of
cells positive for siRNA uptake. In addition, increasing the amount of folate used to
decorate siRNA-containing liposomes further decreased the fraction of cells positive for
siRNA uptake after treatment with those liposomes (Figure 3.9B). The decreased siRNA
uptake may be at least partly attributable to decreased encapsulation of siRNA in
complexes treated with folate: Cy3 siRNA is red in colour, and folate-decorated
liposome:siRNA complexes were visibly less intensely coloured in solution than
liposome:siRNA complexes without folate (data not shown), suggesting that less Cy3siRNA was entrapped in folated liposomes. This was theoretically possible, since
negative charge would be increased in DSPE molecules associated with folate and that
negative charge might repel similarly negatively-charged siRNA. Regardless of the
delivery agent, A549 cells all had >98% of cells positive for Cy3-siRNA uptake,
suggesting that too high a concentration of liposomes was being used to allow
identification of differences in uptake mediated by FR (Figure 3.9B, white bars). This
was further exemplified when treatment with either non-targeting (i.e., no folate) or
folate-decorated liposomes resulted in >80% and >95% of cells being Cy3-siRNA
positive in KB and A549 cells, respectively (Figure 3.10). The high level of siRNA
uptake, as seen is the large peak shift in Figure 10A, was unusual. When DOTAP sources
were investigated it was apparent that the DOTAP used to generate the liposomes was
concentrated to a degree much higher than manufacturer specifications and, therefore,
had increased the overall positivity of the liposomes. The increased positivity would have
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Figure 3.9. Effect of increasing liposome folate decoration on the cellular uptake of
Cy3-siRNA. Non-folated and folate-decorated liposomes were synthesized according to
the “passive encapsulation” protocol. Folate was added directly to the lipid film layer
prior to extrusion. FR positive (KB) and FR negative (A549) cell lines were grown in 6
well plates for 24 hours and transfected for 4 h before being harvested for flow
cytometry.
A) Histogram showing gating of KB cells treated with fol(3X)-Cy3-C2RNA. 74.2% KB
cells positive for Cy3-siRNA uptake, 25.8% negative.
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents.
non-fol-Cy3-C2RNA – non-targeting liposomes
fol(1X)-Cy3-C2RNA – folate decorated liposomes
fol(3X)-Cy3-C2RNA – folate decorated liposomes with 3X as much folate added
One experiment, n = 3.
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Figure 3.10. Effect of high DOTAP concentration on the cellular uptake of Cy3siRNA. Non-folated and folate-decorated liposomes were synthesized according to the
“passive encapsulation” protocol. Folate was added directly to the lipid film layer prior to
extrusion. FR positive (KB) and FR negative (A549) cell lines were grown in 6 well
plates for 24 hours and transfected for 4 h before being harvested for flow cytometry.
A) Histogram showing gating of an individual A549 sample treated with fol(1X)-Cy3C2RNA. 99.9% A549 cells positive for Cy3-siRNA uptake, 0.113% negative.
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents.
non-fol-Cy3-C2RNA – non-folated, non-targeting liposomes
fol(1X)-Cy3-C2RNA – folate-decorated liposomes
fol(3X)-Cy3-C2RNA – folate-decorated liposomes with 3 times as much folate added as to
fol(1X)-Cy3-C2RNA.
One representative experiment of several, n = 3.
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been expected to increase non-specific uptake of all liposomes, regardless of folate status,
due to strong interaction with negatively-charged plasma membranes. A fresh batch of
DOTAP was purchased and used in future experiments.
In addition to the issue of DOTAP concentration, there remained the observation
that no difference in cellular uptake of liposome-encapsulated siRNA between nonfolated and folate-decorated liposomes in the FR-positive KB cell line (Figure 3.8).
Literature reports indicate that the majority of folate added to medium surrounding FRexpressing cells is taken up within the first hour of addition and then plateaus130,131.
Therefore, to assess whether addition of folate to liposomes increased uptake into FRpositive cells in a time-dependent fashion, uptake at earlier times was tested (Figure
3.11). In accord with published reports130,131, folate-decorated liposomes, especially when
folate was added after the extrusion process, were taken up by FR-positive KB cells as
soon as 30 m after addition and continued to be taken up by cells up to 2 h after addition.
Non-folated liposomes delivered siRNA to less than 10% of KB cells up to the 1 h after
addition, although approximately 30% of cells received siRNA by 2 h post-addition. This
suggests that the greatest difference in uptake between non-targeting and folate-decorated
liposomes might be achieved within the first hour of addition of liposomes to cells. All
subsequent experiments were performed with a transfection time of 30 m. In addition,
increasing the amount of folate by addition of folate directly to the lipid film layer before
extrusion reduced Cy3 siRNA uptake (Figure 3.9B). On the other hand, increasing the
amount of folate after extrusion increased Cy3 siRNA uptake (Figure 3.11B). These data
suggest that post-extrusion incubation with folate is desirable as a folate-decoration
strategy.
To further explore addition of folate after liposome extrusion as a strategy to
increase uptake of liposome-encapsulated siRNA, a partial repeat of Figure 3.11B was
carried out with the desired treatment groups. Non-folated liposomes and liposomes
prepared using two concentrations of folate added after liposome extrusion were
generated. They were then added to FR-positive KB cells for 30 minutes and siRNA
uptake into those cells was assessed (Figure 3.12). The addition of folate following the
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Figure 3.11. Effect of incubation time on the cellular uptake of liposome:Cy3-siRNA
complexes into FR-positive KB cells. Non-folated and folate-decorated liposomes were
synthesized according to the “passive encapsulation” protocol. FR-positive KB cells were
grown in 6 well plates for 24 hours and incubated with liposome:siRNA complexes (C2:
non-targeting scrambled control siRNA) for 30 m, 1 h, or 2 h before being harvested for
flow cytometry.
A) Histogram showing gating of an individual KB sample treated with fol(1X)-Cy3C2RNA (after) at 30 m. 70.2% KB cells positive for Cy3-siRNA uptake, 29.8% negative.
B) Percentage of cells positive for Cy3-siRNA uptake using various delivery agents.
non-fol-Cy3-C2RNA – non-targeting liposomes
fol(1X)-Cy3-C2RNA (before) – folate added to lipid film layer prior to extrusion
fol(1X)-Cy3-C2RNA (after)– folate added following the extrusion process
fol(3X)-Cy3-C2RNA (after)–3X the amount of folate added following the extrusion
process.
One experiment, n = 3.
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Figure 3.12. Effect of increasing liposome folate decoration following extrusion on
the cellular uptake of Cy3-siRNA. Non-folated and folate-decorated liposome:siRNA
complexes were synthesized according to the “passive encapsulation” protocol. Folate
was incubated with liposomes for >1 h following extrusion. FR-positive (KB) cells were
grown in 6 well plates for 24 hours and transfected for 30 m before being harvested for
flow cytometric analysis of Cy3-labeled siRNA uptake.
A) Histogram showing gating of an individual KB sample treated with fol(3X)-Cy3C2RNA. 72.9% KB cells positive for Cy3-siRNA uptake, 27.1% negative.
B) Percentage of cells positive for Cy3 siRNA using various delivery agents
non-fol-Cy3-C2RNA – non-targeting liposomes
fol(1X)-Cy3-C2RNA – folate decorated liposomes
fol(3X)-Cy3-C2RNA – folate decorated liposomes with 3X as much folate added
Two experiments, n = 6
*p<0.05 compared to non-fol-Cy3-C2RNA
**p<0.05 compared to fol(1X)-Cy3-C2RNA
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extrusion process increased the percentage of KB cells positive for Cy3 siRNA by ~30%
and increasing the amount of folate added to the liposomes by 3X further enhanced Cy3siRNA positivity by another ~20%. To take the analysis further, and to assess whether
liposomes prepared with folate added after extrusion would target siRNA delivery to FRpositive cells more effectively than to FR-negative cells, a wider range of folate
concentrations were added to liposome aliquots following extrusion and the resulting
folated liposome:siRNA complexes added to both FR-positive KB and FR-negative A549
cells (Figure 3.13). Figures 13A and 13B are different representations of the same data
for ease of comparison either within the same cell line or between the two, respectively.
Decorating the liposomes with folate significantly increased Cy3 siRNA uptake in both
KB and A549 cells (Figure 3.13A). However, the increase was greater in the FR positive
KB cell line at all folate concentrations (Figure 3.13B). Furthermore, increasing the
amount of folate added to the liposomes up to 6 times more than the initial level of added
folate enhanced Cy3 siRNA uptake in a folate concentration-dependent manner, while
increasing the amount of folate from 1X to 6X did not increase siRNA uptake in the FRnegative A549 cell line (Figure 3.13A).
3.2.3 Non-targeting and folate decorated liposome tissue/organ distribution
following systemic administration in nude mice.
To complement the in vitro uptake data, the biodistribution of the liposome
particles was assessed after tail vein (systemic) administration. An amount of 0.035:50
molar mass DOTAP:Cy3-C2RNA liposome/siRNA mixture (5 nmol siRNA per injection
prior to extrusion) was injected into nude mice and, after 6 h, mice were sacrificed for
tissue collection. The KB tumours (Figure 3.14a) and liver, spleen, connective tissue
(surrounding tumour), kidney, and muscle (Figure 3.14b) were removed and placed in
plastic cassettes containing O.C.T for cryosectioning. The samples were then cut into 10
μm thick sections and photographed immediately using a fluorescence microscope. There
was limited fluorescence in both the non-folated and folate-decorated liposome treated
KB xenografts. Subjectively, KB tumours treated with the non-targeting liposome may
have a higher Cy3 siRNA fluorescence than tumours treated with the folate-decorated
liposomes (Figure 3.14A). However, this cannot be quantified due to a lack of overall
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Figure 3.13. Effect of increasing folate concentrations used to functionalize
liposomes after extrusion on cellular uptake of Cy3-siRNA. Non-folated and folatedecorated liposomes were synthesized according to the “passive encapsulation” protocol.
Folate was incubated with liposomes for >1 h following extrusion. FR-positive (KB) and
FR-negative (A549) cells were grown in 6 well plates for 24 hours and treated with
siRNA:liposomal preparations for 30 min before being harvested for flow cytometric
analysis of siRNA uptake.
A) Histogram showing gating of an individual KB sample treated with fol(10X)-Cy3C2RNA. 75.9% KB cells positive for Cy3-siRNA uptake, 24.1% negative.
B) Bar graph of percentage of cells positive for Cy3 siRNA using range of folate
concentrations added after extrusion to compare within same cell lines
C) Line graph showing percentage of cells positive for Cy3 siRNA after treatment with
liposomes prepared using a range of folate concentrations added after extrusion to
compare between cell lines (different representation of same data in B)
non-fol-Cy3-C2RNA – non-targeting liposomes
fol(1X)-Cy3-C2RNA – folate decorated liposomes
fol(3X)-Cy3-C2RNA – folate decorated liposomes with 3X as much folate added
fol(6X)-Cy3-C2RNA – folate decorated liposomes with 6X as much folate added
fol(10X)-Cy3-C2RNA – folate decorated liposomes with 10X as much folate added.
Two experiments, n = 6
A: p<0.05 compared to non-fol-Cy3-C2RNA in KB cells
B: p<0.05 compared to fol(1X)-Cy3-C2RNA in KB cells
C: p<0.05 compared to fol(3X)-Cy3-C2RNA in KB cells
D: p<0.05 compared to non-fol-Cy3-C2RNA in A549 cells
*: p<0.05 compared to corresponding folate concentrations in A549 cells
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Figure 3.14. Tissue/organ distribution of non-targeting and folate decorated
liposomes containing Cy3 siRNA. Mice were inoculated with 2 million KB cells
(Section 2.16) and euthanized on day 27. Six h prior to euthanasia, mice were
systemically (tail vein) injected with 0.035:50 molar mass DOTAP:Cy3-C2RNA
liposome/siRNA mixture (5 nmol siRNA per injection prior to extrusion). KB xenografts
and tissues were harvested from similar areas on each mouse and placed in a plastic
cassette containing OCT (freezing media). The samples were then frozen at -80oC and cut
in 10 μm sections for fluorescence microscopy to visualize fluorescent Cy3 C2 siRNA
accumulated in tissues.
A) Representative images of KB xenograft tumours in 3 of the mice per treatment
group
B) Representative images of selected tissues from the organs of a selected mouse
(only one used as fluorescence patterns were similar across mice)
6 mice per treatment group.
Magnification 100X
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fluorescence observed within individual images and variability between imaged sections
(some sections displayed no fluorescence). The other organs with the highest
fluorescence were the liver and spleen, which is expected because organs in the
reticuloendothelial system preferentially accumulate systemically injected
nanoparticles60. Unexpectedly, fluorescence was only observed in muscle treated with
non-targeting liposomes, which may have only been an artifact of the non-targeting
treatment group containing a higher initial concentration of Cy3-siRNA. Images were
also taken of the kidney, where cationic liposomes have been know to accumulate132.
However, due to autofluorescence from the tissue itself, no fluorescence attributable to
Cy3 siRNA accumulation could be confirmed (data not shown).
3.3 Ability of liposome:targeting siRNA complexes to knock down a gene target
3.3.1 Antisense effect of liposomes delivering TS siRNA payload in vitro
Before testing the liposome formulations for their ability to effectively
downregulate TS transcript levels, the functionality of the TS siRNA (TSRNA) in KB
and A549 cells (both of which express TS) was verified using a proven commercial
liposomal delivery system (Lipofectamine 2000)(Figure 3.15). As reported previously
using this anti-TS siRNA in A549 and other cell lines28, TS transcript levels were
reduced by ~80%. TS knockdown in KB cells is shown for the first time.
Measurement of TS mRNA before and after treatment with liposome:siRNA
complexes indicated that the liposomes were not able to downregulate TS mRNA levels
24 hours after addition of complexes (results not shown and Figure 3.16). The use of
PEG in liposomes, although desirable to increase liposome:siRNA time in circulation
time and to inhibits RES entrapment, might also abrogate siRNA- mediated mRNA
degradation by preventing escape of internalized siRNAs from endosomes60. To assess
possible PEG inhibition of siRNA activity, both PEGylated and non-PEGylated
liposomes were formulated and tested for their silencing ability in KB and A549 cell lines
at 24 h post-addition (Figure 3.16). Neither PEGylated nor non-PEGylated liposomes
were able to downregulate TS mRNA levels in either of the cell lines. To confirm that the
liposome:siRNA complexes were capable of entering cells , fluorescent images were
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Figure 3.15. Relative quantity of TS mRNA transcript s following treatment with TS
siRNA delivered using Lipofectamine 2000 (LF2K). KB and A549 cells were grown in
6 well plates for 24 h. Cells were then transfected with TS siRNA for 4 h using LF2K.
Fresh media was added to the wells and 24 h later the cells were harvested for
measurement of TS mRNA (GAPDH used as endogenous control) by qPCR.
LF2K C2RNA – transfected with LF2K containing 10 nM control siRNA
LF2K TSRNA – transfected with LF2K containing 5 nM control siRNA and 5 nM TS
RNA
One experiment, n = 3.
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Figure 3.16. TS mRNA transcript levels following treatment with PEGylated and
non-PEGylated liposomes. Non-folated and folate-decorated liposome:siRNA
complexes were synthesized according to the “passive encapsulation” protocol. The
PEGylated liposomes were then coated with DSPE-PEG. KB and A549 cells were grown
in 6 well plates for 24 h. Cells were then treated with treated with complexes for 4 h. 24 h
later the cells were harvested for real-time PCR.
A) TS mRNA levels in KB cells
B) TS mRNA levels in A549 cells
non-fol-Cy3-C2RNA (+PEG) – non-targeting liposomes containing control siRNA and
coated with PEG
non-fol-Cy3-C2RNA (+PEG) – non-targeting liposomes containing control siRNA and
no PEG on surface
non-fol-Cy3-TSRNA (+PEG) – non-targeting liposomes containing TS siRNA and
coated with PEG
non-fol-Cy3-TSRNA (+PEG) – non-targeting liposomes containing TS siRNA and no
PEG on surface
fol-Cy3-C2RNA (+PEG) – folate decorated liposomes containing control siRNA and
coated with PEG
fol-Cy3-C2RNA (+PEG) – folate decorated liposomes containing control siRNA and no
PEG on surface
fol-Cy3-TSRNA (+PEG) – folate decorated liposomes containing TS siRNA and coated
with PEG
fol-Cy3-TSRNA (+PEG) – folate decorated liposomes containing TS siRNA and no PEG
on surface
One experiment, n = 2.
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taken 24 h following transfection (Figure 3.17). The liposomes used were non-PEGylated
in order to maximize uptake and increase potential to downregulate TS. From the images,
it is evident that the cells took up a significant amount of Cy3-TS siRNA. To confirm that
siRNA was not confined to target cell surfaces without entry into cell interior, several
samples were analyzed by confocal microscopy through several planes. Confocal images
confirmed that siRNAs were present in cytoplasm (data not shown).
Knowing that the siRNA delivered using liposomes entered target cells, it was
possible that endocytosed liposome:Cy3 siRNA particles required longer than 24 h to
escape the endosomal compartment and enter cytoplasm and interact productively with
RISC complexes. Therefore, cells were harvested 48 h after siRNA: liposome complex
addition and assessed for TS mRNA knockdown by qPCR (Figure 3.18b). Additionally,
and in order to promote endosomal escape, the liposomes were synthesized with higher
degrees of DOTAP (increased positivity) and the fusogenic lipid DOPE was added (see
end of Section 2.1 in Introduction for discussion of factors affecting endosomal escape).
The presence of protamine was also investigated to determine whether the stable complex
it formed with the siRNA might interfere with siRNA activity (Figure 3.18). Only nontargeted liposomes were synthesized in an attempt to generate TS downregulation of any
degree before using reagents to make targeted liposomes. No significant reduction in TS
mRNA levels was observed after treatment with any of the liposome formulations at
either 24 or 48 hours. Although treatment with TS siRNA:liposome formulations
containing 4X DOTAP and DOPE resulted in TS mRNA levels that trended to decrease,
that did not induce significant differences. It is possible that increasing the positivity and
amount of DOPE used to generate liposomes might be a fruitful strategy to lead to target
mRNA knockdown.
3.3.2 Antisense effect of liposomes delivering TS siRNA payload in vivo
The formulated liposomes were unable to downregulate TS mRNA levels in vitro.
However, circumstances in vivo are different. Therefore, and while assessing the
biodistribution of liposomes in vivo, TS mRNA levels in KB tumour xenografts were
analyzed following a 4 week treatment course where liposome:Cy3 siRNA complexes
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Figure 3.17. Fluorescent images of KB cells transfected with liposome/Cy3-siRNA.
Non-folated and folate-decorated liposome:siRNA complexes were synthesized
according to the “passive encapsulation” protocol. KB cells were cultured for 24 h in 6
well plates and then transfected for 4 h to maximize uptake. 24 h later the cells were
washed 2X with PBS to remove any excess liposome:siRNA. The cells and siRNA
uptake were then imaged by fluorescence microscopy. The blue background in the
overlay images is an artifact generated by the computer program software.
Magnification 200X
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Figure 3.18. TS mRNA transcript levels 24 and 48 h after treatment with various
liposomal formulations. Non-folated liposome:siRNA complexes were synthesized
according to the “passive encapsulation” protocol. KB cells were grown in 6 well plates
for 24 h. Cells were then treated with complexes for 4 h. 24 or 48 h later the cells were
harvested for real-time PCR.
A) TS mRNA levels in KB cells 24 h after transfection
B) TS mRNA levels in KB cells 48 h after transfection
DOT 2X C2RNA (+prot) – liposomes with 2X the amount of DOTAP included carrying
control siRNA complexed with protamine
DOT 2X TSRNA (+prot) – liposomes with 2X the amount of DOTAP included carrying
TS siRNA complexed with protamine
DOT 2X C2RNA (-prot) – liposomes with 2X the amount of DOTAP included carrying
control siRNA with no protamine
DOT 2X TSRNA (-prot) – liposomes with 2X the amount of DOTAP included carrying
TS siRNA with no protamine
DOT 2X, DOPE C2RNA (+prot) – liposomes with 2X the amount of DOTAP and DOPE
included carrying control siRNA complexed with protamine
DOT 2X TSRNA (+prot) – liposomes with 2X the amount of DOTAP and DOPE
included carrying TS siRNA complexed with protamine
DOT 4X C2RNA (+prot) – liposomes with 4X the amount of DOTAP included carrying
control siRNA complexed with protamine
DOT 4X TSRNA (+prot) – liposomes with 4X the amount of DOTAP included carrying
TS siRNA complexed with protamine
LF2K C2RNA – transfected with LF2K containing 10 nM control siRNA
LF2K TSRNA – transfected with LF2K containing 5 nM control siRNA and 5 nM TS
RNA.
One experiment, n = 2.
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were injected twice per week in mouse tail veins. The mice were then sacrificed on day
27 and the KB xenografts were harvested for RNA isolation and qPCR (Figure 3.19).
Similar to the results seen in vitro, no TS downregulation was observed in any of the
treatment groups in vivo. The lack of downregulation would have likely been further
compounded by the limited uptake in tumour tissue as observed in the biodistribution
study (Figure 3.14A).

104

Figure 3.19. TS mRNA levels in KB xenografts from nude mice following systemic
liposome:Cy3 TS siRNA administration. Mice were inoculated at 2 sites with 2 million
KB cells and sacrificed on day 27. Mice were systemically injected (tail vein) with
0.035:50 molar mass DOTAP:Cy3-TSRNA liposome:siRNA complexes once per week
for 4 weeks. KB xenografts were harvested from each mouse and frozen at-80oC.
Sections of tumour were thawed and RNA was isolated for qPCR analysis of TS mRNA
levels (GAPDH used as endogenous control).
non-fol-Cy3-TSRNA – non-targeting liposomes containing TS siRNA
fol-Cy3-C2RNA – folate decorated liposomes containing TS siRNA
fol-Cy3-TSRNA – folate decorated liposomes containing TS siRNA.
6 mice per treatment group, 2 tumours per mouse.

105

106

Chapter 4

4

Discussion
The purpose of this work was to assess the ability of folate functionalized

liposomes to deliver TS siRNA to the RNAi machinery of FR-positive cancer cells to
activate its antisense effect. We initially hypothesized that our non-targeting liposomes
will facilitate siRNA uptake into cells more efficiently than naked siRNA alone.
Subsequently, decoration of liposomes with folate ligand will enhance their ability to
deliver siRNA to FR-positive human tumour cells both in vitro and in vivo as a method to
increase antisense activity over non-targeting vehicles. In this section I will discuss
implications of the physical attributes of the liposome particles [Section 4.1: particle
charge and size (Section 4.1.1), levels of folate decoration (Section 4.1.2), siRNA
encapsulation yields (Section 4.1.3), serum nuclease protection (Section 4.1.4)]; analysis
of cellular uptake and biodistribution studies [Section 4.2: choice of cells lines (Section
4.2.1), troubleshooting lack of FR-mediated enhancement of uptake (Section 4.2.2)]; and
challenges faced with TS mRNA transcript knockdown (Section 4.3).
4.1 Implications of liposome physical characteristics
4.1.1 Measurements of particle charge and size
The non-targeting and folate decorated liposomes were determined to have zeta
potentials in the range of 30-35 mV and diameters spanning from 130-150 nm. These
values have varying implications depending on whether in vitro or in vivo liposome
uptake and cargo delivery is being optimized. For example, in vitro, a higher positive zeta
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potential or surface charge usually equates with higher cellular uptake133,134 and greater
toxicities135 due to interactions with the negatively-charged plasma membrane on cells. In
an in vivo setting, liposomes with an increased positive charge have been reported to
correlate with enhanced accumulation in the liver: a consequence that may be
undesirable, depending on the where delivery is desired (in this case, undesirable because
delivery to tumour and not liver is the goal). However, and even with increased liver
uptake, increased positive charge on liposomes has been shown to enhance uptake by
tumour vasculature compared to neutral or anionic liposomes132,136. This correlates with
the in vivo biodistribution of positively-charged liposomes I observed, because the
highest amount of Cy3 siRNA fluorescence could be seen in the liver tissue (Figure
3.14B). Particles with zeta potentials greater than 30 mV are considered strongly cationic
and this strength of electrostatic repulsion has been linked to greater stability over time
and resistance to the tendency of particles to aggregate over time and increase in size137.
In fact, the data showing liposome stability over time is positive and encouraging. The
liposomes remained stable up to 6 h and had begun to aggregate only 12 h after synthesis
(Figure 3.2C). Remaining stable in solution for longer than a few hours was critical to
ensuring that aggregation did not taken place from the time of synthesis to the time of
addition to cells in culture or tail vein injection into whole animals: an interval likely to
be several hours under normal circumstances. On the other hand, if the particles are too
stable it can prevent siRNA release into the cytosol once taken up by the cell138.
There is some debate as to the size of liposomes for optimal delivery to tumour
tissue. Some researchers believe particles should be less than 100 nm104, while others
would argue a diameter less than 200 nm is sufficient for effective in vivo delivery133,139.
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Sizes over 200 nm have been shown to switch from a clathrin-dependent mechanism of
endocystosis to a caveolae-dependent uptake mechanism, and this could influence
cellular uptake depending on mechanisms available in target cell populations140. In
addition, the maximum size of particles capable of escaping leaky tumour vasculature
varies depending on tumour type, but typically falls somewhere in the range of 200-600
nm141,142. Particles larger than this size would have a difficult time taking advantage of
the EPR effect to accumulate at the tumour environment (see Section 1.6 for further
explanation of EPR effect and challenges of delivery). Therefore, the non-targeting and
folate-decorated liposomes fall within a size range that should allow for effective use
both in vitro and in vivo. However, it will be important to conduct an in vivo study
comparing the biodistribution of current liposomes versus those of smaller size resulting
from further extrusion using 50 nm pores.
4.1.2 Low folate insertion in liposomes
It was surprising that less than 10% of the DSPE-PEG-folate that was added to the
liposomes either before extrusion or after was inserted in the liposomes (Section 3.1.2).
Some research groups have reported between 60-90% folate insertion with their postinsertion techniques143-145. If 100% of the DSPE-PEG-folate was inserted into liposomes,
then the folate-decorated liposomes would have an overall folate mol% of 0.23, meaning
the actual folate mol% < 0.023% for the liposomes containing the standard amount of
folate (fol(1X)) since less than 10% insertion was observed (Section 3.1.2). This amount
of inserted DSPE-folate-PEG is considerably lower than typically used. However, one
study reported optimal cellular uptake with liposomes bearing as low as 0.03% fol
mol%146. The low amount of incorporated folate may be one reason that folate-decoration
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of liposomes did not enhance uptake in FR-positive KB cells compared to the FRnegative A549 cells (Figure 3.8) unless the amount of folate added following liposome
extrusion was increased (Figures 3.12 & 3.13). Regardless, from data reported in the
literature144,147 and experience gained in the course of these studies, inserting the folate
following extrusion allows for better control and folate decoration exclusively on the
outside of the liposome (rather than both in the interior and on the exterior), compared to
adding it directly to the lipid layer. Direct addition of folate to the lipid prior to exclusion
results in folate incorporation roughly equally on the exterior and in the interior of the
lipid bilayer, thus reducing the amount of exterior folate available for binding to target
cell folate receptors147.
4.1.3 Assessing siRNA encapsulation yield
Using the passive encapsulation protocol for liposome synthesis, generally 3-40%
of antisense molecules will become encapsulated depending on the lipid constituents and
overall charge of the particles148-150. Incorporation of 100% of siRNA in the interior
would be unexpected because, theoretically, 50% of siRNA molecules should attach to
the interior of the liposome as it forms and 50% should interact with the exterior. In
addition, the extrusion process is relatively inefficient at associating siRNA with
liposomes, as evidenced by pink colouring on filters (due to the pink colour of Cy3
siRNA visible to the naked eye) after extrusion (subjective observation, data not shown).
Therefore, a roughly 44% siRNA encapsulation percentage as indicated by the
RiboGreen assay (Table 3.2) is relatively successful in terms of siRNA:liposome
association. However, due to certain limitations of the RiboGreen assay (discussed
above) the degree of association may be overestimated. Regardless, a higher percentage
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of siRNA in liposomes achieved using this method, compared to other passive
encapsulation methods, is not unexpected as the liposomes have a strong cationic charge.
That charge would facilitate electrostatic interactions with the negatively charged siRNA.
4.1.4 Prolonged protection of siRNA against serum nucleases
The ability of both the non-targeting and folate decorated liposomes to protect
siRNA from nuclease degradation up to 48 h was significant for two reasons. First,
systemically-injected liposomes must pass though circulation before reaching their target
tissues, so siRNA degradation soon after exposure to serum would render the therapy
ineffective. Second, in many cases it can take anywhere from 12-24 h for liposome
particles to reach and accumulate in the tumour microenvironment, and siRNA protection
from nucleases remains essential during the period of time after arrival at target tissues
and uptake into target cells151,152.
4.2 Folate decoration on uptake and biodistribution studies
4.2.1 Choice of cell lines
It has become common practice in testing the efficacy of folate-ligated particles to
use the FR-positive KB cell line as well as a low FR-expressing cell line, such as
A549145,153,154. The presence of the low FR expressing cell line, A549, helped to
determine whether cell-specific, FR-independent differences in uptake between the
targeting and folate-decorated liposomes are important considerations that would
otherwise have been overlooked if only the FR-positive KB cells were used to determine
differences in uptake between folate-positive and folate-negative liposomes. FR
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expression was also measured in cells exposed to folate-depleted media for 3 h prior to
exposure to siRNA:liposome preparations, to ensure that their FR levels were not
upregulated by lack of folate (a possible cellular response to low folate). Upregulation
would not have been expected during this very short time, but an increase in FR levels of
over tenfold has been reported within 24 hours of folate depletion155.
4.2.2 Troubleshooting enhancement of FR-mediated uptake
One of the two greatest challenges with this project was achieving an enhanced
uptake in the FR-positive KB cells when exposed to folate-decorated liposomes,
compared to non-folated non-targeting liposomes. The first major breakthrough on this
front came when the liposome exposure time was reduced. The literature indicated that
FR-mediated endocytosis occurs primarily within the first hour of exposure to
liposomes130,131, while the non-specific uptake of cationic liposomes still increases past 4
hours156. This is likely due to FR-mediated uptake being an active process versus passive
general endocytosis. Since reducing the time to 30 minutes enhanced the difference in
uptake between the folate-decorated and non-folated non-targeting liposomes (Figure
3.11) it is hypothesized that part of the lack of enhancement seen previously (Figures 3.8
& 3.9) may have been due to the non-targeting liposomes and/or both non-targeting and
targeting liposomes reaching maximal uptake at some point during a 4 hour period of
exposure to cells (i.e., a "plateau" effect obscuring differences that would have been
evident before plateaus are reached). Furthermore, it was encouraging to see that
increasing the amount of folate added to the liposomes increased cellular uptake in the
KB cells, but not in the A549 cells (Figure 3.13), similar to reports of others154,157.
Additionally, decorating the liposomes with any amount of folate caused a greater
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increase in uptake in the KB (~40%) cells than compared to the A549 cells (~10%). The
observed 10% increased in uptake of the folate decorated liposomes in FR-negative A549
cells further reinforces the usefulness of the strategy of including a negative control in the
experiment, as it is likely that folate decoration also enhances uptake to some degree via a
non-FR-mediated interaction (e.g., steric hindrance, surface charge).
As mentioned previously, cationic liposomes have been shown to preferentially
accumulate in the liver132,158. It was unsurprising, then, that the biodistribution study
revealed an abundance of Cy3 siRNA fluorescence in the biopsied liver tissue (Figure
3.14B). Cationic liposomes also have a propensity to localize in the spleen, especially
after saturating the liver, which is expected as these are the major players of the RES
system132,159. Indeed, the results reported here are consistent with that. Unfortunately,
there did not appear to be a higher fluorescence of Cy3 siRNA delivered by folatedecorated liposomes to the FR-positive KB tumours compared to delivery by nontargeting liposomes. In fact, the tumours in animals treated with siRNA-containing but
non-folated (non-targeting) liposomes may have accumulated a larger amount of siRNA
(with subjectively-assessed higher fluorescence overall)(Figure 3.14A). However, if true,
this could also be due to slightly higher amounts of Cy3 siRNA loaded into the nonfolated liposomes (compared to folated liposomes), although they were prepared side by
side and under identical conditions. Another possible factor contributing to lack of
differences in accumulation of non-folated and folate-decorated liposomes in tumours
could be the amount of folate ligand exposed on the liposomes and available for binding
to receptors. The data from the in vitro uptake studies showed that uptake increased in
FR-positive KB cells when folate decoration was increased post extrusion (Figures 3.12
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& 3.13). On the other hand, the in vivo biodistribution study was performed with
liposomes where folate was inserted directly into the lipid film layer prior to extrusion,
meaning that less folate would have accumulated on the outside of the liposome and been
available for binding. Several studies indicate that decorating particles with a targeting
ligand does not increase accumulation of liposomal cargo molecules in the tumour
environment, compared to similar non-targeting particles. However, targeting does
increase active uptake in tumour cells themselves, which helps to overcome inhibition of
non-specific endocytosis due to the EPR effect. As a result, one would expect to see nontargeting liposomes accumulate in the interstitium and connective tissue surrounding the
tumour and more targeted liposomes penetrating the actual tumour152,160. Therefore,
assuming that folate decoration was low on the targeting liposomes, it is not surprising to
see the non-targeting liposomes accumulate in tumour tissues to the same extent as their
targeting counterparts (Figure 3.14A). At the same time it was disappointing that no
fluorescence was observed in the connective tissue in close proximity to the tumour,
which likely has more to do with a low overall amount of liposome/Cy3 siRNA that
reached the tumour area.
4.3 Challenges of achieving an antisense effect (transcript knockdown) in cells
The second major obstacle faced in this project was the inability of the nontargeting or folate decorated liposomes to achieve TS transcript downregulation both in
vitro and in vivo. Initially, the thought was that a new batch of Cy3 TS siRNA obtained
from Dharmacon might have an incorrect, non-complementary sequence. However,
testing with a commercially-available transfection reagent (Lipofectamine 2000)
indicated that the siRNA was able to downregulate TS mRNA in A549 cells when not

114

encapsulated in the liposomes tested in this study (Figure 3.15). Another possibility was
that temperature fluctuations between 50-70oC during the extrusion process could have
degraded the siRNA and rendered it ineffective, but non-modified siRNA has been
shown to maintain its integrity and function after exposure to temperatures reaching 95oC
and after temperature cycling from low to high161. As mentioned previously, the
incorporation of PEG, while useful, can also impede endosomal escape60. Therefore, nonPEGylated liposomes were synthesized in an attempt to maximize the potential for TS
mRNA downregulation. The absence of PEG, however, did not result in a reduction in
TS transcript levels in cells treated with siRNA:liposomes. We also varied the time
between exposure of cells to targeting siRNA:liposome preparations and harvesting the
cells for qPCR, based on the hypothesis that a longer time for liposomes to achieve
endosomal escape to release siRNA payload into cytoplasm, but this modification did not
result in siRNA effectiveness. It appears, from fluorescent microscope images, as though
a great deal of siRNA had been taken up by the cell and, in some cases, the fluorescence
pattern was punctate, suggesting containment in endosomes162-164 (Figure 3.17). A
punctate pattern is not completely diagnostic of endosomal entrapment, however, and
cannot be considered sufficiently strong evidence that this is the actual cause for lack of
transcript downregulation. While not statistically significant, an increase in the amount of
positive DOTAP used and the inclusion of the fusogenic lipid DOPE appeared to result in
a trend to decreased TS mRNA levels (Figure 3.18A) suggesting that increasing their use
could potentially further decrease target mRNA levels. This would not be surprising, as
an increase in DOTAP has been shown to increase liposomal uptake efficiency165. As
utilized in other studies a way to test whether the issue is, in fact, a lack of endosomal
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release, may be by incubation with influenza-derived fusogenic peptide diNF-7166 or
exposure of siRNA:liposome preparations to cells in conjunction with photochemical
internalization (PCI)163, both of which are proven methods to facilitate endosomal
release. diNF-7 undergoes a conformational change at lower pHs due to protonation and
the resulting complex fuses with endosomes, thus facilitating their destabilization. PCI
relies on photosensitizer molecules that accumulate in endosomes and become activated
upon exposure to blue light, whereby they produce singlet oxygen species that bind the
membrane and increase its permeability167. If, however, these have no effect, then the
problem may arise from other causes, such as siRNA degradation once following cell
internalization or a lack of liposome-siRNA release preventing proper RISC
incorporation even if they are able to escape the endosome. The first problem could be
tested by first conjugating siRNA with biotin and then following a 24 h transfection
isolating the biotin-siRNA using streptavidin beads168 and re-transfect them using a
proven commercial agent (Lipofectamine) to determine if they are still functional. The
second potential issue could be investigated indirectly by incubating liposome-siRNA
complexes in serum or various pH buffered solutions and measuring changes in free
siRNA, by RiboGreen, for example169. If no siRNA is being released, perhaps the
liposomes are too stable and unable to efficiently release their payload.
The non-targeting and folate-decorated liposomes were characterized according
to their surface charge, size, stability and ability to protect siRNA against nuclease
degradation. Quantification of the amount of siRNA encapsulated is insufficiently precise
and continues to require refinement. Some strategies to achieve more accurate readings
could include adding a highly anionic molecule (i.e. heparin) to outcompete siRNA for
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lipid/protamine binding so it can freely bind the RiboGreen dye, or, modify RNA
isolation kits that utilize filter/ultracentrifuge techniques to concentrate siRNA170.
Enhanced uptake of folate-decorated liposomes compared to their non-targeting
counterparts in FR positive human cells was achieved by increasing the amount of folate
inserted into their outer leaflet over a shortened time of exposure of siRNA:liposomal
constructs to target cells. Unfortunately, downregulation of TS mRNA levels using TS
siRNA:liposome preparations was not achieved in spite of preferential uptake by FRpositive cells. However, the data suggest possible causes of lack of effectiveness of
siRNA delivered using liposomal methods and areas for future study.
This work required a great deal of troubleshooting especially in the early stages to
achieve enhanced delivery of folate decorated liposomes to FR positive cancer cells
compared with non-targeting particles. Keeping this in consideration, the enhanced
uptake with our folate decorated liposome may not have been as great as reported in
some of the literature144,155, however, I would caution fellow researchers to consider the
physiological relevance of the cell cultures commonly used. The gold standard in the
literature appears to be KB or cells synthetically transfected with high FR expressing
vectors grown and maintained in folate depleted media171,172, which promotes FR
upregulation and may indeed have rendered these cells far more addictive to folate than
the physiological folate levels exposed to normal or malignant FR expressing cells124.
Therefore, I think this work can be used to help bring the study of FR-mediated uptake to
other FR expressing cancer types and the probable realistic gains that can be achieved.
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